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Targeting the, chromatin modifying enzyme, Histone deacetylase 6 has been a strategy that is 
recently identified to treat several cancers such as liver, lung and other tumours. Besides 
deacetylating histones, the enzyme also acts on proteins such as HSP90, Cortactin and α-
tubulin that are involved in tumorigenesis. The present study combines the techniques of 
structure based and ligand based virtual screening methods to identify new drug compounds 
that could selectively inhibit HDAC6. The second catalytic domain of the enzyme was 
modelled and docking studies were performed on it with the compounds obtained from 
literature. The results of the docking were employed to screen the compounds for building a 
pharmacophore model. The Pharmacophore model was utilized in identifying 106 
compounds from drugbank as hits. A genetic algorithm based QSAR model was developed to 
further screen the hits identified to 58 based on predicted activity. Free binding energy 
estimation was done for the 58 compounds and the poses with best binding energy and 
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1.1.2. Epigenetics  
The term epigenetics relates to heritable changes in the gene expression without any actual 
change in the sequence of the DNA or in its expressed proteins.[1, 2] It takes control of 
expression and repression of the genes based upon the cues obtained from the environment. 
Some of the notable examples currently known are X- Chromosome inactivation in female 
mammalians, Identical twins diverging considerably as they age on, differential coat colours 
observed in female calico cats. It encompasses events such as DNA Methylation, Post 
translational modification to histone tails such as Acetylation, Methylation, Ubiquitination, 
Phosphorylation, Sumoylation etc. and small non coding RNA (miRNA, siRNA).[3] 
Epigenetics plays a crucial role in the developmental process of a eukaryotic organism such 
as cellular differentiation and proliferation, it is also actively involved in the maintenance of 
several genes such as expression and silencing of Tumour suppression genes and oncogenes 




DNA Methylation is a process where methyl groups are added to Cytosine bases at CpG 
dinucleotide domains. Methylation of CpG dinucleotides generally leads to gene silencing, at 
the same time DNA hypermethylation at promoter regions may lead to repression of Tumour 
suppression genes (TSGs) which further promotes tumorigenesis. In Contrast reduced 
methylation of genes, hypomethylation affects the stablility of the genome by allowing 




Post Translational Modifications at Histone Domains 
 
146 base pairs of DNA is tightly wrapped around the octamer consisting four pairs of Histone 
subunits H2A, H2B, H3 AND H4.[6, 7] Each Histone domain is connected through a linker 
DNA. From the N-terminal region protrudes histone tail where a wide array of Post 
Translational Modifications (PTMs) occur. PTMs refers to covalent modification of histone 
tails by addition or removal of chemical groups such as acetyl, methyl etc at specific residues. 
PTMs play a crucial role in positioning of chromatin, which in turn affects the accessibility of 
genes to transcription factors.[8] Out of several PTMs, Histone acetylation/deacetylation and 
Histone methylation/ demethylation has been widely studied and best understood. 
1.1.3. Histone Deacetylases (HDACs) 
 
Histone Deacetylases (HDACs) are a family of enzymes that catalyse the removal of acetyl 
groups from the amino terminal of lysine residues of histone tails. This results in tighter 
wrapping of DNA around the histone octamer and blocking the access of DNA by 
Transcription Factors (TFs).[9] In contrast Histone acetyl transferases (HATs) produces an 
opposite effect by adding negatively charged acetyl groups to positively charged lysine 
residues.[10] This allows the DNA to free itself from the histone octamer and thereby binding 





Figure 1. The two main components of epigenetics, DNA methylation and Histone 
modification. 
Apart from its natural substrate Histone, HDACs target a wide range of proteins involved in 
regulatory functions such as cell cycle, cytoskeletal stability, cell proliferation, cell motility 
and apoptosis.[11, 12] Considering the fact that it plays a crucial role in the above functions, 
any aberrations could lead to serious conditions such as Cancer. HDACs has been the target 
of several inhibitors in the treatment of various cancers since overexpression of HDACs 
represses the expression of Tumour Suppressor Genes (TSGs).  
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18 different HDACs has been identified so far and are classified into four classes base upon 
their identity to yeast histone deacetylases.[9, 13] HDAC 1, 2, 3 and 8 are nuclear enzymes 
classified under Class I. Class II has two subclasses within,  Class IIa and Class IIb 
containing HDAC 4, 7 and 9 and HDAC 6 and 10 respectively. Class II enzymes can shuttle 
between nucleus and cytoplasm. Class III also called Sirtuins are NAD+ dependent enzymes 
which includes Sirt 1 – 7. HDAC 11 the lone enzyme has been classified into Class IV. 
HDACs belonging to the Class I, II and IV are Zinc dependent proteins which is important 
for their catalytic activity. 
 
Figure 2. Classification of Histone Deacetylase (HDAC) family. Class I, II and IV are zinc 
dependent enzymes whereas Class III are NAD dependent enzymes. 
1.1.4. Histone Deacetylase Inhibitors 
 
As earlier mentioned HDACs are involved in the progression of variety of cancers such as 
breast cancer, colon cancer and several other solid tumours, there has been growing need to 
discover new inhibitors of HDACs.[14-16] Most of the inhibitors currently being targeted are 
small molecular compounds such as Hydroxamates, benzamides, carboxylates etc.,  At 
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present U.S Food and Drug Adminstration (FDA) has approved two drugs Vorinostat or 
SAHA and romidepsin in the treatment of Cutaneous T-Cell Lymphoma[17, 18]. Various 
other inhibitors are in the various stages of clinical trials. Despite with several potential 
inhibitors ready to be available, none of them are specific to any HDACs and all are 
categorised as pan inhibitors of HDACs. It has been found that pan inhibitors lead to several 
side effects such as nausea, anorexia, fatigue, anemia, cardiac arrhythemias and ECG changes 
when taken as a drug, which is understandable with the wide range of regulatory functions 
HDACs take part in.[16, 19] 
The present study states the need to discover drugs specific to HDAC isoforms. HDAC6, a 
class IIb enzyme has been implicated in Oral Squamous cell cancer, Breast cancer, lung 
cancer, hepatocellular carcinoma etc., which are mostly due to anomalies related to 
deacetylase activity towards its key substrates such as α-tubulin, β-Catenin, HSP90 and 
Cortactin.[20-22] 
1.1.5. Computer Aided Drug Discovery (CADD) 
 
On an average, the US Pharmaceutical industry spends around US $60 billion in the search of 
new drugs for diseases such as Cancer, AIDS, Alzheimer’s and Malaria. A new drug in order 
to hit the market, it will take around 10 – 15 years and US $500 – 800. It is a huge challenge 
in terms of time and money.[23, 24] A prospective drug may fail at any stage of clinical trials 
and may even be withdrawn after being approved if any concomitant reactions are observed. 
So it has been a norm for every pharmaceutical industry to reduce cost and save time with the 
help of computational power.  
Since there are millions of compounds – synthetic and biological available in various 
databases, it is almost impossible to try out each compound experimentally for its ability in 
being a possible drug for a particular disease. Computational approach helps in screening out 
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most of the unlikely and unfeasible compounds during the vey initial stages of drug 
discovery. This approach has also been termed as Virtual Screening, it generally precedes the 
High throughput screening approach which is generally adopted. It basically optimizes the 
chances of lead identification with little expenditure and limited amount of time. Virtual 
Screening could be either Structure based or Ligand Based or sometimes both the approaches 
could be adopted together. Here again the input for any theoretical study like this is again 
data from experimental studies such as Protein Structure from crystallography or NMR , IC50 
values from inhibiton studies etc.[25-27] 
1.1.5.1. Structure Based Drug Discovery 
 
It has been the typical and widely used approaches for potential lead identification and 
discovery. The data for this approach is protein structure obtained through X-Ray 
Crystallography, NMR or Homology Modelling Studies. Here a diverse set of small 
molecules are docked into the macromolecule by predicting the binding site of the protein. 
The docked protein-ligand complexes are analysed for their affinity and binding energy, best 
conformations and their hydrogen bonding ability. With those parameters the best docked 
pose will be identified and taken for further in-silico toxicity assays or for High Throughput 
Screening depending upon the number of screened compounds available in hand. 
Molecular Docking 
 
Docking is the most extensively used method in the rational drug design process to find out 
new compound that fits the profile of a drug for a particular disease. The preliminary 
requirement for a docking program is protein structure obtained from X-Ray Crystallography 
or NMR Spectroscopy or a Modelled protein using the sequence available in NCBI databases. 
The next step is predicting and analysing binding site of the protein using online servers 
available for this. The two basic components of any docking program are Search algorithm 
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and scoring function. The search algorithm predicts the best conformations for a compound to 
fit into the binding site and the Scoring function ranks the ligand conformations based upon 
their binding affinities.[28] 
1.1.5.2. Ligand Based Drug Discovery 
 
This approach is regarded as indirect one, where the structure of the target protein is not 
available and drug discovery is mainly carried out with the input of activity data available 
through experimental results. The methods that come under this approach are Pharmacophore 
modelling and Quantitative Structure Acitivity Relationship (QSAR). 
Pharmacophore Modelling 
 
According to IUPAC, a pharmcophore could be defined as “an ensemble of electronic and 
steric features that is necessary to ensure optimal supramolecular interactions with a specific 
biological target and to trigger its biological response ”[29]. It searches for different 
conformations in a compound library and will try to match different pharmacophore features 
such as Hydrogen bond donor, Hydrogen bond acceptor, Negative Ionizable area, Positive 
Ionizable area, hydrophobic interactions, Aromatic Ring, Metal binding location. A model is 
built based upon the matched features between the compounds and the same model is latter 
used to screen large databases in search of similar compounds.[30] 
Quantitative Structure Activity Relationship 
QSAR is a statistical model which gives a mathematical equation that describes the relation 
between the structure, which is given in a mathematical form called descriptors and 
Biological or physic-chemical properties of the compound. The equation is later used to 
predict properties such as Biological Activity, Log P etc. QSAR models are also called 
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regression models which gives an R squared value based on the linearity of the compounds 





i. To model the second catalytic domain of the enzyme Histone deacetylase6 
with the Modeller. 
ii. Minimizing the energy of the protein using Gromacs. 
iii. Developing a Ligand – based pharmacophore model to search for compounds 
with similar pharmacophoric features in various database. 
iv. To predict activity of the identified hits through a genetic algorithm based 
QSAR model. 
v. Estimate the binding efficiency of the screened compounds and their 
































2. Literature Review 
 
2.1.  Post Translational Modification at Histone Tails 
 
Histone proteins are subjected to a wide array of post translational modifications which 
affects the chromatin position and there after transcription status of genes. Four pairs of 
histone proteins H2A, H2B, H3 and H4 forms an octamer and is wrapped around by DNA to 
form a nucleosome molecule. Out from the surface of histone protein protrudes a tail region 
which is the target of post translational machinery.[33-35] Histone tails comprise around 30% 
of the total individual mass of histone are found to protease sensitive.[36, 37] Methylation, 
Acetylation, Phosphorylation, Sumoylation, Ubiquitination and ADP ribosylation are PTMs 
that take place on histone tails.  
2.2.  Histone Deacetylases (HDACs) 
 
Histone deacetylases (HDACs) also called Lysine Deacetylase (KDACs) mediates the 
regulation of gene expression by compacting the DNA around the hisone octamers. This is 
achieved by removal of acetyl groups from the ε-N- terminal of lysine residues on histone 
tails. Apart from histone they also deacetylase several other regulatory proteins which are 
involved in cell proliferation, cell differentiation, cytoskeletal stability and cell motility [38, 
39]. In contrast Histone acetyl transferases (HATs) perform antagonistic functions by adding 
acetyl groups to the histone tails and allowing the DNA to free itself of histone octamers and 
make itself available for transcription [40, 41]. 
Around two decades before, Yoshida et al., has identified TSA induces differentiation and 
cell cycle arrest in cultured cells [42]. It was also found that TSA while inducing 
differentiation it actually inhibits HDAC, later Richon et al also observed hyperacetylated 
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proteins due to inhibition of HDACs [43]. In 2007, suberoylanilide hydroxamic acid (SAHA, 
vorinostat) was discovered as a drug to treat Cutaneaous T cell lymphoma while inhibiting all 
11 classical HDACs. It was also found that the HDAC inhibitors have no toxic effects on 
normal cells but only on transformed cells [44]. Since then a large group of researchers have 
sought to discover new potential inhibitors of HDACs in the treatment of breast cancer, colon 
cancer, lung cancer and other tumours. 
2.3. Histone Deacetylase 6 
 
HDAC6 has been identified as cytoplasmic protein which apart from its natural substrate 
histone catalyses the deacetylation of α-tubulin which is associated with microtubulin 
network. The above process has direct influence on cytoskeletal stability and it the enzyme is 
also referred to as Tubulin Deacetylase due to its action [12, 13, 45]. In addition to α-tubulin, 
HDAC6 catalyses various cytoskeletal proteins such as HSP90, Cortactin, β-Catenin, Ku70 
etc. [46-49]. HDAC6 is inhibited by Vorinostat and TSA, but lack of selectivity towards the 
enzyme particularly over HDAC1 prevents it being taken as potent inhibitors. Tubacin and 
Tubastatin A were found to have shown selectivity towards HDAC6, but due to their poor 































3.1. Homology Modelling of HDAC6 
Histone Deacetylase 6 (HDAC6) has been identified as cytosolic protein and it has sequence 
length of 1215 amino acid residues. HDAC6 was found to possess two catalytic domains 
CD1 and CD2 with residue positions from 73 - 455 and 479 – 845 respectively. It was also 
further identified that the Catalytic Domain 2 (CD2) is the main site for substrate 
deacetylation. Currently there is no crystal structure of HDAC6 with any of the catalytic 
domain is available. Homology modelling of CD2 of HDAC6 was performed with the 
template chosen as 3C0Y, crystal structure of HDAC7 which was available in the Protein 
Data Bank. 
The Query sequence of HDAC6 was obtained from Uniprot and was later trimmed to include 
sequence of only CD2. Homology Modelling was done using Modeller 9.11, a freely 
available software.[52] It is a program which does comparative protein structure by 
satisfaction of spatial restraints. The query sequence was performed blast analyses to such for 
template structures in PDB with similar sequences. These template sequences were fed into 
Modeller along with the query sequence where it performed multiple sequence alignment and 
zeroed in on 3C0Y as template based upon the root mean square difference. Five models 
were generated using the chosen template, and the best model was selected by evaluating 
Dope score and GA341 score. 
3.2. Validation of Homology Model 
The model generated using Modeller was validated using Rampage 
[http://mordred.bioc.cam.ac.uk/~rapper/rampage.php] and Prosa[53], both online servers. 
Rampage assess the quality of protein structure by analysing it through Ramachandran plot. 
The protein structure in pdb format was given as input and it generates a plot with percentage 
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of residues present in favoured, allowed and outlier regions. On the other hand Prosa 
calculates Z-score and gives the output in the form of a plot with the Z-scores of all 
experimental derived structures. The quality of modelled protein is assessed by looking at the 
position while corresponding to experimental structures (X-Ray  
Crystallography and NMR). 
3.3. Energy Minimization of Protein 
The energy minimization of modelled protein was done using Gromacs 4.6.5, a molecular 
dynamics and simulation package in Linux environment.[54, 55] The topology file for the 
protein was prepared and a cubic box is generated with dimension of 0.7 d. The protein was 
put into the box and was solvated using water molecules. Gromos53a6 [56] forcefield was 
chosen and algorithm as Steepest descent to perform minimization.[57] 1000 steps was given 
for the steepest descent algorithm to converge the protein to its minimal energy state. 
3.4. Virtual Screening of compounds targeting HDAC6 
3.4.1. Molecular Docking 
An exhaustive literature search has led to the identification of 819 compounds that showed 
varied inhibitory potential (Ranging from 0.002 – 68000 nM) against HDAC6.The residues 
that are involved in the active site were identified and the x,y and z coordinates of the active 
site residue was obtained. Autodock Vina, a freely available program was used to perform 
docking.[58] Compared to Autodock 4.2.1, Vina was reported to significantly increase the 
accuracy of the binding mode. The pdbqt files for the receptor and ligands were prepared 
using Autodock 4.2.1 in a batch manner. The pdbqt files and x, y and z coordinates of the 
receptor were fed to vina in a batch manner to perform docking for 819 compounds. 
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3.4.2. Ligand based pharmacophore modelling 
Pharmacophore model generation was accomplished by Ligandscout 3.1.[59] The dataset for 
model generation was obtained by filtering out compounds from the docked results. 
Compounds having binding energy less than -7.0 and molecular weight less than or equal to 
600 were discarded and the remaining 164 compounds were retained as dataset. 
Conformations for the compounds was generated by Omega, a component inbuilt in 
ligandscout with fast settings. The number of conformations to be generated was given as 25, 
RMS threshold was given as 0.8 and the rest of the settings being default. 
3.4.2.1. Training Set and Test Set 
For a successful pharmacophore model, preparation of training set with diverse features is 
crucial. 13 compounds having features such as Hydrogen bond acceptor, Hydrogen bond 





Figure 3. Training set molecules with features HBA, HBD, Hydrophobic and Negative 
ionisable areas used to develop pharmacophore model. 
3.4.2.2. Model Generation 
Pharmacophore model was generated with training set having 13 compounds. The scoring 
fuction was selected as Pharmacophore fit and atom overlap and Merged feature 
pharmacophore was chosen as Pharmoacophore type. The number of omitted features was 
given as 3 and exclusion volumes were allowed to be created. With other all settings being 




3.4.2.3. Database Search for identification of hits 
Creating and Loading database 
Drugbank, a database for in-silico virtual screening contains 6381 compounds with more than 
1500 being FDA approved. The compounds are freely available for downloading as Stucture 
data file (sdf). A database for Drugbank compounds was created in ligandscout from the 
structure data file. This database was further loaded into screening module of ligandscout for 
screening of compounds using the built pharmacophore. 
Database Screening 
The pharmacophore generated having top score was copied to screening perspective and 
performed screening to select molecules from Drugbank with similar pharmacophoric 
features. The Scoring function was selected as Pharmacophore-fit and screening mode was 
selected as match all query features. The maximum number of omitted features was given as 
zero and exclusion volumes was selected. 
3.4.3. Quantitative Structure Activity Relationship 
QSAR was performed to further screen the hits from drug bank identified through 
pharmacophore model. McQSAR, an open source software was employed for this.[60] 
McQSAR gives the output as a mathematical equation which is evolved over a sequence of 
generations using Genetic algorithm. 
3.4.3.1. Model Generation 
128 diverse set of compounds with activities ranging from 1 to 10000 nM were obtained from 
the literature and assigned as training set to develop QSAR model. The inputs for the 
program are descriptor file for the training set and an activity file corresponding to that. The 
descriptors for the training set was calculated using Padel Descriptor, a free java based tool. 
The parameter to be predicted by McQSAR is assigned as IC50 and the other settings such as 
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mutation probability and number of generations were given as 0.05 and 100 respectively. The 
rest other settings were default ones.  
3.4.3.2. Prediction of activity 






 should be 
greater than 0.6 and Q
2 
should be greater than 0.6). As the value of R
2
 approaches 1, it 
indicates the linearity of model and its statistical predictability. The generated equation that 
describes the relation between the compounds and its activity was taken from the best model. 
The prediction run was carried by giving the equation file the compounds for which activity 
to be predicted as inputs. The activities for the hits obtained from Drugbank were predicted. 
3.4.4. Estimation of Free Binding energy 
Out of 106 Drugbank compounds for which activity has been predicted, 58 compounds were 
selected by screening compounds with Predicted IC50 in the range of 1 – 1000 nM. Docking 
was performed using Autodock Vina, the x, y and z active coordinates of the modelled 
protein was given and the compounds were docked in a batch process one by one. The 






















4.1. Homology Modelling 
The BLAST search for structures with similar sequences has returned 7 proteins with more 
than 40 % identity. Out of those three structures, 2VQO, 4CBY and 3C0Y were further 
selected for modelling. A alignment file was generated between query sequence and template 
sequences. Later five models were generated by using the automodel class of modeller. The 
best model HDAC6.B99990002 was selected by evaluating the models with low DOPE 
potential score. 

























 Figure 4. Five models generated by Modeller with three proteins 2VQO, 4CBY and 3C0Y 
as template structures. The best model is the one with the lowest DOPE potential score. 
4.1.1. Validation of Homology Model 
The validation of the model HDAC6.B99990002 by Rampage has showed around 0.3% 
residues lying in the outlier region which is pretty common in the modelled proteins. The 
overall model quality was predicted by PROSA, which gave a Z-Score of -7.81 which is in 


























Rampage for the modelled protein, showing percentage of residues lying in the Favoured, 




                        
Figure 6: Quality of model assessed using PROSA, the black dot at the centre represents 
modelled protein. 
4.2. Energy Minimization of Protein 
The steepest descent algorithm of GROMACS took 588 steps to converge the protein to its 
minimal energy state. The initial potential energy of the protein was found to be -6.57902 * 
10^5 and the final potential energy was found to be -1.0628135 * 10^06. The energy plot was 
generated using Grace Program which is depicted below and the water from the solvated 
protein was removed using Rasmol[61, 62]. 
 
              Figure 7. Plot depicting energy minimization of protein by Gromacs 
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4.3. Molecular Docking 
The active site residues of the protein was identified as HIS611 AND CYS618 through 
Uniprot. The coordinates of the HIS611 was taken as binding site position. The binding 
energies and docked conformations of 819 compounds were estimated by docking the 
compounds to the macromolecule. The table below shows all the compounds along with their 





Table 1. Top ten binding affinities of the docked complexes. 
Compound_Id 
Top Ten Docked Conformations 
1 2 3 4 5 6 7 8 9 10 
CHEMBL496924 -9.3 -8.6 -8.3 -8.2 -8.2 -8.2 -8.1 -8.1 -8 -8 
CHEMBL141082 -9.1 -8.2 -8.2 -8.1 -7.9 -7.9 -7.9 -7.8 -7.8 -7.7 
CHEMBL1812335 -9.1 -8.5 -8.5 -8.5 -8.3 -8.3 -8.2 -7.8 -7.8 -7.8 
CHEMBL466031 -9.1 -8.2 -8.1 -8 -7.9 -7.8 -7.8 -7.8 -7.6 -7.6 
CHEMBL98 -9.1 -8.8 -7.8 -7.8 -7.7 -7.6 -7.6 -7.6 -7.6 -7.3 
CHEMBL1487 -8.9 -8.7 -8.6 -8.5 -8.4 -8.3 -8.1 -8.1 -8.1 -8 
CHEMBL1164243 -8.8 -8.8 -8.5 -8.5 -8.2 -8.2 -8 -7.9 -7.8 -7.5 
CHEMBL468842 -8.7 -8.5 -8.2 -8.2 -8.1 -8.1 -8.1 -8.1 -8 -7.9 
CHEMBL481878 -8.7 -8.6 -8.6 -8.5 -8.4 -8.2 -8.1 -8.1 -8 -7.9 
CHEMBL2333345 -8.6 -8.3 -8 -8 -7.9 -7.7 -7.6 -7.6 -7.6 -7.5 
CHEMBL1214763 -8.5 -8.1 -8.1 -7.9 -7.7 -7.7 -7.7 -7.5 -7.5 -7.5 
CHEMBL2047544 -8.5 -7.9 -7.7 -7.5 -7.4 -7.3 -7.2 -7.2 -7.1 -7 
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CHEMBL567220 -8.5 -8.5 -8.4 -7.8 -7.8 -7.8 -7.7 -7.7 -7.6 -7.5 
CHEMBL1797983 -8.4 -7.8 -7.7 -7.7 -7.6 -7.1 -7.1 -7.1 -7.1 -7 
CHEMBL363528 -8.4 -7.2 -7.1 -7.1 -7.1 -7.1 -7 -7 -7 -7 
CHEMBL466033 -8.4 -8.1 -7.9 -7.9 -7.8 -7.7 -7.7 -7.7 -7.7 -7.7 
CHEMBL494645 -8.4 -8.1 -7.9 -7.9 -7.6 -7.5 -7.5 -7.4 -7.3 -7.2 
CHEMBL1094707 -8.3 -8.2 -8.1 -8 -7.9 -7.8 -7.8 -7.8 -7.8 -7.7 
CHEMBL2158744 -8.3 -6.9 -6.7 -6.6 -6.5 -6.5 -6.4 -6.4 -6.3 -6.3 
CHEMBL430060 -8.3 -7.9 -7.7 -7.6 -7.6 -7.5 -7.4 -7.3 -7.3 -7.3 
CHEMBL515432 -8.3 -8.2 -7.6 -7.2 -7.1 -7 -6.9 -6.7 -6.7 -6.7 
CHEMBL569193 -8.3 -7.8 -7.7 -7.7 -7.7 -7.6 -7.6 -7.6 -7.4 -7.4 
CHEMBL1094709 -8.2 -8 -7.9 -7.8 -7.8 -7.8 -7.8 -7.5 -7.5 -7.5 
CHEMBL2047699 -8.2 -7.7 -7.7 -7.6 -7.6 -7.6 -7.4 -7.3 -7.1 -7.1 
CHEMBL404172 -8.2 -8.1 -8 -8 -8 -7.9 -7.9 -7.9 -7.9 -7.8 
CHEMBL99 -8.2 -7.8 -7.3 -7.3 -7.3 -7.3 -7.3 -7.2 -7.2 -6.9 
CHEMBL2047539 -8.1 -7.9 -7.7 -7.6 -7.6 -7.3 -7.3 -7.2 -7.2 -7.2 
CHEMBL2047541 -8.1 -7.7 -7.5 -7.3 -7.2 -7.2 -7.1 -7 -7 -6.9 
CHEMBL1289931 -8 -7.6 -7.4 -7.3 -7.2 -7.2 -7.1 -6.8 -6.7 -6.7 
CHEMBL1800382 -8 -7.6 -7.1 -7 -6.9 -6.7 -6.7 -6.5 -6.5 -6.5 
CHEMBL2347009 -8 -6.9 -6.7 -6.3 -6.3 -6.2 -6.2 -6.2 -6.2 -6.2 
CHEMBL261492 -8 -7.2 -7 -6.9 -6.9 -6.8 -6.8 -6.7 -6.6 -6.6 
CHEMBL272980 -8 -7.8 -7.7 -7.5 -7.4 -7.2 -7 -7 -7 -6.9 
CHEMBL473891 -8 -7.5 -7.4 -7.4 -7.3 -7.3 -7.3 -7.3 -7.2 -7.2 
CHEMBL507716 -8 -8 -7.6 -7.1 -7.1 -7 -7 -7 -6.8 -6.6 
CHEMBL519668 -8 -7.5 -7.1 -6.9 -6.9 -6.9 -6.8 -6.6 -6.5 -6.5 
CHEMBL567295 -8 -7.4 -7.4 -7.2 -7.2 -7.2 -7.2 -7.1 -7.1 -7.1 
CHEMBL1087053 -7.9 -7.7 -7.7 -7.6 -7.5 -7.4 -7.3 -7.3 -7.3 -7.2 
CHEMBL1822042 -7.9 -7.8 -7.7 -7.7 -7.6 -7.4 -7.3 -7.2 -7.1 -7.1 
CHEMBL2337873 -7.9 -7.8 -7.6 -7.5 -7.5 -7.5 -7.5 -7.5 -7.3 -7.2 
CHEMBL2337875 -7.9 -7 -6.9 -6.8 -6.8 -6.6 -6.6 -6.6 -6.6 -6.5 
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CHEMBL235082 -7.9 -7.8 -7.4 -7.2 -7.2 -7.2 -7.1 -7.1 -7.1 -6.8 
CHEMBL259708 -7.9 -7.6 -7.6 -7.6 -7.3 -7.2 -7.1 -7.1 -7 -7 
CHEMBL408513 -7.9 -7.1 -7.1 -7 -7 -7 -6.9 -6.9 -6.9 -6.6 
CHEMBL466171 -7.9 -7.3 -7.1 -7.1 -7.1 -7 -7 -7 -7 -6.8 
CHEMBL475392 -7.9 -7.5 -6.9 -6.8 -6.6 -6.5 -6.3 -6.3 -6.3 -6.3 
CHEMBL475820 -7.9 -6.9 -6.7 -6.6 -6.5 -6.5 -6.4 -6.4 -6.4 -6.3 
CHEMBL481703 -7.9 -7.5 -7.5 -7.5 -7.3 -6.9 -6.8 -6.7 -6.6 -6.6 
CHEMBL492312 -7.9 -7.9 -7.7 -7.6 -7.6 -7.2 -7.2 -7 -6.9 -6.9 
CHEMBL493871 -7.9 -7.4 -6.8 -6.6 -6.5 -6.5 -6.5 -6.4 -6.4 -6.4 
CHEMBL566641 -7.9 -7.8 -7.8 -7.6 -7.6 -7.5 -7.3 -7.3 -7.2 -7.2 
CHEMBL571140 -7.9 -6.9 -6.9 -6.9 -6.8 -6.8 -6.8 -6.7 -6.6 -6.5 
CHEMBL571507 -7.9 -7.8 -7.3 -7.1 -7.1 -7 -6.9 -6.9 -6.9 -6.8 
CHEMBL1099058 -7.8 -7.5 -7.3 -7.3 -7.3 -7.3 -7.3 -7.2 -7.2 -7.1 
CHEMBL1767045 -7.8 -7.3 -7.2 -7.2 -7.2 -7.1 -7 -7 -6.8 -6.8 
CHEMBL1800381 -7.8 -7.7 -6.7 -6.6 -6.5 -6.5 -6.5 -6.5 -6.4 -6.4 
CHEMBL480729 -7.8 -7.4 -6.9 -6.9 -6.7 -6.6 -6.6 -6.6 -6.4 -6.3 
CHEMBL493784 -7.8 -7.4 -7.4 -7.3 -7.3 -7.1 -7.1 -7 -7 -6.9 
CHEMBL570490 -7.8 -7.6 -7.4 -7.2 -7.1 -7 -7 -7 -6.9 -6.9 
CHEMBL1094792 -7.7 -7.2 -7.2 -7.2 -6.9 -6.8 -6.8 -6.6 -6.6 -6.5 
CHEMBL1095400 -7.7 -7.6 -7.3 -7 -6.8 -6.7 -6.7 -6.7 -6.7 -6.6 
CHEMBL141885 -7.7 -7.6 -7.4 -7.2 -7.2 -7.2 -7.2 -7.2 -7.1 -7.1 
CHEMBL16300 -7.7 -7.3 -7.3 -7.3 -7.2 -7 -6.9 -6.9 -6.9 -6.4 
CHEMBL1836142 -7.7 -7.3 -6.9 -6.9 -6.8 -6.5 -6.5 -6.5 -6.4 -6.4 
CHEMBL1836144 -7.7 -7.6 -6.7 -6.6 -6.5 -6.5 -6.5 -6.4 -6.4 -6.4 
CHEMBL2023526 -7.7 -7 -6.8 -6.7 -6.2 -6.2 -6.2 -6.1 -6 -6 
CHEMBL2046456 -7.7 -7.3 -7.1 -7 -6.9 -6.5 -6.4 -6.4 -6.3 -6.3 
CHEMBL2152613 -7.7 -7.4 -7.3 -7.3 -7.2 -7.1 -7.1 -7 -7 -7 
CHEMBL2158741 -7.7 -7.7 -7.6 -7.6 -7.5 -7.5 -7.5 -7.5 -7.3 -7.3 
CHEMBL227119 -7.7 -7.4 -7.1 -7 -6.9 -6.8 -6.4 -6.4 -6.4 -6.4 
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CHEMBL2333344 -7.7 -7.4 -7.4 -7.4 -7.2 -7.2 -6.8 -6.8 -6.6 -6.6 
CHEMBL454671 -7.7 -7.5 -7.4 -7.3 -7.1 -7.1 -6.8 -6.8 -6.8 -6.7 
CHEMBL482095 -7.7 -7.7 -7.3 -7 -6.7 -6.7 -6.7 -6.6 -6.6 -6.6 
CHEMBL482358 -7.7 -6.9 -6.6 -6.6 -6.5 -6.3 -6.1 -6.1 -6 -6 
CHEMBL493315 -7.7 -7.6 -7.6 -7.5 -7.4 -7.3 -7.1 -7 -6.9 -6.8 
CHEMBL514511 -7.7 -7.5 -7.4 -7.4 -7.4 -7.3 -7.2 -7.2 -7.1 -7.1 
CHEMBL569446 -7.7 -7.2 -7.2 -7.1 -7.1 -7 -6.9 -6.9 -6.9 -6.8 
CHEMBL1088734 -7.6 -7.3 -7.2 -7.2 -6.9 -6.8 -6.7 -6.4 -6.3 -6.3 
CHEMBL2023527 -7.6 -7.4 -7.3 -7.2 -7.2 -7.1 -7 -6.9 -6.9 -6.8 
CHEMBL2047674 -7.6 -6.9 -6.5 -6.5 -6.5 -6.5 -6.5 -6.4 -6.3 -6.3 
CHEMBL2047703 -7.6 -7.5 -7.3 -7.1 -7.1 -7 -6.9 -6.7 -6.6 -6.6 
CHEMBL2048749 -7.6 -7.5 -7.3 -7.2 -7.2 -7.1 -7.1 -6.9 -6.9 -6.9 
CHEMBL2312167 -7.6 -7.4 -7.2 -7 -6.9 -6.9 -6.8 -6.8 -6.7 -6.7 
CHEMBL235842 -7.6 -7.3 -7.3 -6.9 -6.7 -6.6 -6.6 -6.5 -6.4 -6.4 
CHEMBL466644 -7.6 -6.8 -6.7 -6.7 -6.7 -6.6 -6.5 -6.5 -6.4 -6.4 
CHEMBL471042 -7.6 -7.2 -7.2 -7.1 -6.7 -6.6 -6.6 -6.6 -6.6 -6.6 
CHEMBL484489 -7.6 -7.1 -7 -6.9 -6.8 -6.7 -6.7 -6.7 -6.6 -6.6 
CHEMBL486324 -7.6 -7.3 -7.2 -7.1 -7.1 -7 -6.9 -6.8 -6.8 -6.8 
CHEMBL1091474 -7.5 -7.3 -7.2 -7.1 -7 -6.9 -6.9 -6.9 -6.7 -6.5 
CHEMBL1094152 -7.5 -7.2 -7.1 -7 -6.7 -6.6 -6.5 -6.4 -6.4 -6.3 
CHEMBL1800385 -7.5 -7.3 -7.3 -7.2 -7.2 -7.2 -7 -6.9 -6.9 -6.8 
CHEMBL188007 -7.5 -7.3 -7.2 -7.1 -7 -6.9 -6.8 -6.7 -6.6 -6.6 
CHEMBL2018301 -7.5 -7 -7 -6.9 -6.9 -6.8 -6.7 -6.6 -6.6 -6.6 
CHEMBL213934 -7.5 -6.8 -6.8 -6.8 -6.6 -6.6 -6.6 -6.5 -6.4 -6.4 
CHEMBL2153075 -7.5 -7.4 -7.3 -7.2 -7 -7 -7 -6.9 -6.8 -6.7 
CHEMBL2170018 -7.5 -7.2 -7.1 -7 -7 -6.9 -6.9 -6.9 -6.9 -6.8 
CHEMBL2333343 -7.5 -7 -6.7 -6.7 -6.6 -6.6 -6.5 -6.4 -6.4 -6.4 
CHEMBL475203 -7.5 -7.4 -7.2 -7.1 -7 -7 -6.9 -6.9 -6.9 -6.9 
CHEMBL569633 -7.5 -7.3 -7.1 -7 -6.9 -6.9 -6.7 -6.6 -6.6 -6.5 
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CHEMBL86537 -7.5 -7.1 -7 -7 -6.9 -6.9 -6.9 -6.8 -6.8 -6.8 
CHEMBL1096981 -7.4 -7.3 -7.1 -7 -7 -6.9 -6.8 -6.7 -6.5 -6.5 
CHEMBL1213490 -7.4 -7.3 -7.2 -7.1 -7.1 -6.6 -6.3 -6.3 -6.2 -6.1 
CHEMBL1767036 -7.4 -6.8 -6.4 -6.3 -6.2 -6.2 -6.1 -6 -6 -6 
CHEMBL1767046 -7.4 -6.9 -6.8 -6.7 -6.5 -6.5 -6.5 -6.5 -6.4 -6.3 
CHEMBL2018294 -7.4 -6.4 -6.4 -6.3 -6.3 -6.2 -6.2 -6.2 -6 -5.6 
CHEMBL2153071 -7.4 -6.9 -6.4 -6.3 -6.3 -6.2 -6.2 -6.1 -6.1 -6.1 
CHEMBL2170017 -7.4 -7.2 -7.1 -7 -6.7 -6.5 -6.4 -6.3 -6.3 -6.3 
CHEMBL2177588 -7.4 -7.1 -6.7 -6.6 -6.6 -6.5 -6.5 -6.4 -6.2 -6.1 
CHEMBL248486 -7.4 -6.9 -6.8 -6.5 -6.5 -6.4 -6.4 -6.3 -6.1 -6.1 
CHEMBL251011 -7.4 -7.4 -7.2 -7 -7 -6.9 -6.8 -6.7 -6.6 -6.4 
CHEMBL260653 -7.4 -7.1 -6.8 -6.7 -6.6 -6.6 -6.5 -6.4 -6.3 -6.1 
CHEMBL450362 -7.4 -7.3 -7.2 -7 -6.6 -6.5 -6.4 -5.8 -5.8 -5.6 
CHEMBL487143 -7.4 -7.3 -7.1 -7 -7 -7 -6.9 -6.9 -6.8 -6.7 
CHEMBL525529 -7.4 -7.3 -7 -7 -7 -6.9 -6.9 -6.8 -6.8 -6.7 
CHEMBL569174 -7.4 -7.4 -7.3 -7 -6.8 -6.7 -6.7 -6.7 -6.6 -6.6 
CHEMBL1095085 -7.3 -7.2 -6.8 -6.7 -6.7 -6.7 -6.7 -6.6 -6.6 -6.4 
CHEMBL1099048 -7.3 -7.1 -7.1 -7 -7 -7 -6.9 -6.9 -6.9 -6.7 
CHEMBL1165571 -7.3 -7 -6.9 -6.8 -6.7 -6.7 -6.7 -6.6 -6.6 -6.6 
CHEMBL1307946 -7.3 -6.7 -6.7 -6.5 -6.4 -6.4 -6.2 -6.2 -6.2 -6.1 
CHEMBL1630117 -7.3 -7.1 -7.1 -7 -6.9 -6.8 -6.7 -6.7 -6.7 -6.7 
CHEMBL1767030 -7.3 -7.2 -6.9 -6.9 -6.8 -6.8 -6.8 -6.8 -6.8 -6.7 
CHEMBL2018300 -7.3 -7 -6.8 -6.8 -6.8 -6.7 -6.7 -6.7 -6.7 -6.7 
CHEMBL2018444 -7.3 -7.2 -6.6 -6.4 -6.3 -6.2 -6.1 -6.1 -6.1 -6 
CHEMBL2046617 -7.3 -7.2 -7.2 -7.1 -7.1 -7.1 -7 -7 -7 -6.9 
CHEMBL2046622 -7.3 -7.1 -7.1 -7.1 -7.1 -7.1 -7 -7 -6.9 -6.8 
CHEMBL2047671 -7.3 -7 -6.7 -6.5 -6.4 -6.4 -6.4 -6.3 -6.3 -6.2 
CHEMBL2047676 -7.3 -7.2 -7.1 -6.8 -6.8 -6.8 -6.7 -6.7 -6.6 -6.3 
CHEMBL2048752 -7.3 -7.2 -7.1 -6.9 -6.9 -6.5 -6.5 -6.4 -6.4 -6.3 
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CHEMBL2177582 -7.3 -7.2 -6.9 -6.8 -6.8 -6.8 -6.7 -6.6 -6.6 -6.6 
CHEMBL263884 -7.3 -7 -7 -7 -6.8 -6.8 -6.8 -6.8 -6.8 -6.8 
CHEMBL398420 -7.3 -7.1 -7 -7 -6.9 -6.8 -6.8 -6.7 -6.7 -6.7 
CHEMBL398884 -7.3 -7.1 -7.1 -6.8 -6.6 -6.5 -6.4 -6.3 -6.2 -6.2 
CHEMBL472250 -7.3 -7.2 -7.1 -7 -6.8 -6.8 -6.6 -6.6 -6.4 -6.4 
CHEMBL482280 -7.3 -7.2 -6.9 -6.9 -6.8 -6.8 -6.7 -6.7 -6.6 -6.6 
CHEMBL483494 -7.3 -7 -6.6 -6.4 -6.2 -6.1 -6 -5.9 -5.9 -5.9 
CHEMBL516915 -7.3 -7.2 -7.1 -7.1 -7.1 -7 -7 -7 -6.9 -6.8 
CHEMBL523588 -7.3 -7.2 -7.2 -7.1 -6.7 -6.7 -6.7 -6.6 -6.6 -6.5 
CHEMBL554 -7.3 -7 -6.7 -6.7 -6.6 -6.6 -6.6 -6.5 -6.4 -6.2 
CHEMBL566873 -7.3 -7.2 -7 -6.9 -6.8 -6.7 -6.6 -6.6 -6.5 -6.4 
CHEMBL569211 -7.3 -7.3 -7.2 -7.1 -7.1 -7 -6.9 -6.8 -6.8 -6.7 
CHEMBL83747 -7.3 -7.2 -6.9 -6.9 -6.9 -6.8 -6.6 -6.6 -6.5 -6.5 
CHEMBL1164225 -7.2 -7.2 -7 -7 -7 -6.7 -6.7 -6.7 -6.6 -6.5 
CHEMBL1164241 -7.2 -7 -6.6 -6.5 -6.5 -6.4 -6.4 -6.3 -6.1 -6.1 
CHEMBL1243261 -7.2 -7 -6.7 -6.7 -6.6 -6.5 -6.3 -5.9 -5.8 -5.8 
CHEMBL1289498 -7.2 -7.1 -7 -6.9 -6.9 -6.9 -6.8 -6.8 -6.8 -6.8 
CHEMBL1631910 -7.2 -7.2 -7.2 -7 -7 -6.9 -6.8 -6.8 -6.8 -6.7 
CHEMBL1808673 -7.2 -7.2 -6.6 -6.5 -6.5 -6.5 -6.5 -6.4 -6.3 -6.3 
CHEMBL197774 -7.2 -7 -6.9 -6.8 -6.7 -6.6 -6.6 -6.5 -6.4 -6.3 
CHEMBL2018447 -7.2 -7.1 -6.9 -6.7 -6.6 -6.4 -6.3 -6.3 -6.2 -6.1 
CHEMBL2046619 -7.2 -7.1 -7 -7 -6.8 -6.7 -6.6 -6.6 -6.6 -6.5 
CHEMBL2046623 -7.2 -7 -6.9 -6.9 -6.8 -6.8 -6.6 -6.5 -6.5 -6.3 
CHEMBL2047543 -7.2 -7.1 -6.8 -6.8 -6.7 -6.5 -6.4 -6.2 -6.2 -6.1 
CHEMBL2047695 -7.2 -7.2 -6.8 -6.8 -6.8 -6.8 -6.8 -6.7 -6.6 -6.6 
CHEMBL2047700 -7.2 -7.1 -7 -7 -6.9 -6.8 -6.8 -6.8 -6.7 -6.7 
CHEMBL2170019 -7.2 -7.2 -7.1 -7.1 -7.1 -7 -7 -6.8 -6.7 -6.7 
CHEMBL217651 -7.2 -7 -6.6 -6.3 -6.2 -6.2 -6.2 -6.2 -6.2 -6.1 
CHEMBL227120 -7.2 -7.2 -7.2 -7.1 -7.1 -7 -7 -6.9 -6.9 -6.9 
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CHEMBL2337864 -7.2 -7.1 -7.1 -6.8 -6.5 -6 -6 -6 -5.9 -5.9 
CHEMBL251144 -7.2 -7.1 -6.9 -6.7 -6.7 -6.6 -6.6 -6.6 -6.5 -6.4 
CHEMBL451289 -7.2 -7.1 -6.8 -6.7 -6.3 -6.2 -6.2 -6 -5.9 -5.9 
CHEMBL462203 -7.2 -6.6 -6.6 -6.5 -6.5 -6.4 -6.3 -6.3 -6.2 -6.2 
CHEMBL462208 -7.2 -6.5 -6.5 -6.4 -6.4 -6.4 -6.3 -6 -6 -6 
CHEMBL475095 -7.2 -7.1 -7.1 -6.9 -6.9 -6.9 -6.9 -6.9 -6.8 -6.8 
CHEMBL481802 -7.2 -7.1 -7.1 -6.9 -6.9 -6.8 -6.8 -6.6 -6.6 -6.5 
CHEMBL490018 -7.2 -7.2 -6.7 -6.7 -6.6 -6.2 -6.2 -6 -5.8 -5.8 
CHEMBL496094 -7.2 -6.8 -6.5 -6.5 -6.4 -6.4 -6.4 -6.4 -6.3 -6.1 
CHEMBL504161 -7.2 -6.6 -6.5 -6.3 -6.3 -6.3 -6.2 -6.1 -5.9 -5.9 
CHEMBL566637 -7.2 -6.6 -6.6 -6.5 -6.4 -6.3 -6.2 -6.1 -6.1 -6 
CHEMBL1094077 -7.1 -7 -6.6 -6.5 -6.4 -6.3 -6.2 -6.1 -6 -6 
CHEMBL1096033 -7.1 -6.6 -6.6 -6.6 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 
CHEMBL1099049 -7.1 -7.1 -7 -7 -6.8 -6.7 -6.6 -6.6 -6.5 -6.5 
CHEMBL1630112 -7.1 -7 -6.7 -6.7 -6.7 -6.7 -6.7 -6.7 -6.6 -6.6 
CHEMBL1800380 -7.1 -7 -6.8 -6.8 -6.6 -6.6 -6.6 -6.5 -6.5 -6.4 
CHEMBL1836145 -7.1 -6.9 -6.5 -6.2 -6.2 -6.1 -6 -6 -6 -5.9 
CHEMBL1938433 -7.1 -7.1 -7 -7 -6.8 -6.7 -6.6 -6.6 -6.5 -6.5 
CHEMBL2012815 -7.1 -6.9 -6.9 -6.8 -6.6 -6.5 -6.5 -6.3 -6.3 -6.2 
CHEMBL2046613 -7.1 -6.4 -6.4 -6.1 -6 -6 -5.9 -5.9 -5.8 -5.7 
CHEMBL2047670 -7.1 -6.9 -6.8 -6.8 -6.8 -6.8 -6.7 -6.6 -6.6 -6.5 
CHEMBL2047686 -7.1 -6.3 -6.1 -6.1 -6.1 -6 -5.9 -5.9 -5.8 -5.7 
CHEMBL2048750 -7.1 -6.9 -6.1 -5.9 -5.9 -5.7 -5.7 -5.7 -5.6 -5.5 
CHEMBL2153074 -7.1 -6.6 -6.5 -6.5 -6.5 -6.4 -6.4 -6.3 -6.3 -6.3 
CHEMBL2158743 -7.1 -6.4 -6.2 -6.1 -6 -6 -6 -6 -6 -5.9 
CHEMBL2170177 -7.1 -6.9 -6.4 -6.3 -6.2 -6.1 -6 -6 -6 -5.9 
CHEMBL2337874 -7.1 -7.1 -7 -6.9 -6.9 -6.9 -6.8 -6.7 -6.7 -6.6 
CHEMBL264926 -7.1 -6.9 -6.9 -6.8 -6.7 -6.6 -6.6 -6.5 -6.5 -6.4 
CHEMBL27759 -7.1 -6.8 -6.5 -6.5 -6.5 -6.4 -6.4 -6.3 -6.2 -6.2 
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CHEMBL343448 -7.1 -6.8 -6.6 -6.5 -6.4 -6.2 -6 -5.9 -5.9 -5.9 
CHEMBL475293 -7.1 -7 -6.9 -6.9 -6.7 -6.7 -6.5 -6.5 -6.5 -6.5 
CHEMBL480005 -7.1 -6.5 -6.5 -6.3 -6.1 -6 -6 -5.9 -5.9 -5.9 
CHEMBL481922 -7.1 -6.9 -6.7 -6.7 -6.6 -6.5 -6.5 -6.3 -6.3 -6.3 
CHEMBL517076 -7.1 -7 -6.9 -6.8 -6.7 -6.6 -6.6 -6.5 -6.5 -6.5 
CHEMBL569674 -7.1 -7 -6.9 -6.9 -6.8 -6.8 -6.7 -6.6 -6.5 -6.5 
CHEMBL572175 -7.1 -7 -6.8 -6.7 -6.6 -6.5 -6.5 -6.5 -6.4 -6.4 
CHEMBL1099057 -7 -6.7 -6.6 -6.3 -6.2 -6.1 -6.1 -6 -5.9 -5.7 
CHEMBL1099065 -7 -6.8 -6.8 -6.7 -6.6 -6.6 -6.5 -6.5 -6.5 -6.4 
CHEMBL1164671 -7 -6.6 -6.4 -6.3 -6.3 -6.2 -6.2 -6.2 -6.1 -5.9 
CHEMBL139192 -7 -6.7 -6.7 -6.7 -6.6 -6.4 -6.2 -6.2 -6.2 -6.2 
CHEMBL1630111 -7 -6.7 -6.7 -6.6 -6.6 -6.6 -6.6 -6.5 -6.5 -6.4 
CHEMBL1767047 -7 -6.9 -6.4 -6.3 -6.3 -6.3 -6.2 -6.1 -6.1 -6 
CHEMBL1800246 -7 -6.8 -6.7 -6.6 -6.6 -6.6 -6.5 -6.5 -6.5 -6.5 
CHEMBL1836042 -7 -6.8 -6.6 -6.5 -6.5 -6.4 -6.4 -6.3 -6.1 -6.1 
CHEMBL2012814 -7 -7 -6.7 -6.6 -6.4 -6.3 -6.3 -6.2 -6.1 -6.1 
CHEMBL2047681 -7 -6.9 -6.9 -6.9 -6.9 -6.7 -6.7 -6.7 -6.7 -6.7 
CHEMBL2047683 -7 -6.7 -6.6 -6.5 -6.5 -6.5 -6.4 -6.3 -6.3 -6.2 
CHEMBL2179245 -7 -6.9 -6.4 -6.2 -6.2 -6.1 -6.1 -6 -6 -6 
CHEMBL2179616 -7 -6.7 -6.3 -6.2 -6.2 -6 -5.9 -5.9 -5.9 -5.9 
CHEMBL221654 -7 -7 -7 -6.9 -6.9 -6.9 -6.9 -6.9 -6.8 -6.7 
CHEMBL257973 -7 -6.9 -6.9 -6.9 -6.8 -6.8 -6.7 -6.6 -6.6 -6.5 
CHEMBL336935 -7 -6.9 -6.8 -6.7 -6.6 -6.4 -6.3 -6.2 -6.2 -6 
CHEMBL462202 -7 -7 -7 -6.7 -6.7 -6.6 -6.6 -6.6 -6.5 -6.5 
CHEMBL475391 -7 -6.9 -6.9 -6.6 -6.6 -6.4 -6.3 -6.3 -6.2 -6.2 
CHEMBL481805 -7 -6.8 -6.8 -6.7 -6.7 -6.7 -6.7 -6.6 -6.5 -6.4 
CHEMBL487533 -7 -6.9 -6.9 -6.8 -6.8 -6.7 -6.4 -6.4 -6.4 -6.3 
CHEMBL496703 -7 -6.9 -6.8 -6.7 -6.7 -6.5 -6.5 -6.5 -6.5 -6.5 
CHEMBL515109 -7 -6.4 -6.2 -6.2 -6.1 -6 -6 -6 -5.9 -5.9 
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CHEMBL515256 -7 -6.8 -6.7 -6.7 -6.6 -6.6 -6.5 -6.3 -6.3 -6.2 
CHEMBL518957 -7 -7 -6.9 -6.6 -6.4 -6.1 -6 -6 -5.9 -5.9 
CHEMBL518961 -7 -6.8 -6.6 -6.4 -6.4 -6.4 -6.4 -6.1 -6.1 -6.1 
CHEMBL566092 -7 -6.9 -6.8 -6.5 -6.4 -6.3 -6.3 -6.3 -6.2 -6.2 
CHEMBL569812 -7 -6.2 -6 -6 -5.9 -5.8 -5.7 -5.7 -5.6 -5.6 
CHEMBL1097369 -6.9 -6.7 -6.7 -6.7 -6.6 -6.5 -6.4 -6.3 -6.3 -6.2 
CHEMBL113003 -6.9 -6.8 -6.8 -6.8 -6.7 -6.7 -6.7 -6.6 -6.6 -6.6 
CHEMBL1214760 -6.9 -6.6 -6.5 -6.4 -6.3 -6.3 -6.3 -6.2 -6.2 -6.2 
CHEMBL1630110 -6.9 -6.8 -6.7 -6.6 -6.6 -6.6 -6.5 -6.5 -6.4 -6.4 
CHEMBL1631915 -6.9 -6.7 -6.4 -6.4 -6.3 -6.2 -6.1 -6.1 -6.1 -6 
CHEMBL1791401 -6.9 -6.7 -6.6 -6.6 -6.4 -6.3 -6.3 -6.2 -6.2 -6.1 
CHEMBL1800379 -6.9 -6.9 -6.8 -6.6 -6.5 -6.3 -6.2 -6 -6 -6 
CHEMBL1828920 -6.9 -6.8 -6.8 -6.7 -6.7 -6.7 -6.6 -6.5 -6.5 -6.2 
CHEMBL2018297 -6.9 -6.8 -6.7 -6.6 -6.6 -6.6 -6.6 -6.5 -6.5 -6.5 
CHEMBL2046616 -6.9 -6.6 -6.5 -6.4 -6.4 -6.4 -6.1 -6.1 -6 -6 
CHEMBL2047668 -6.9 -6.5 -6.3 -6.3 -6.1 -6.1 -6.1 -6 -6 -6 
CHEMBL406927 -6.9 -6.8 -6.6 -6.6 -6.5 -6.5 -6.4 -6.3 -6.2 -6.2 
CHEMBL407959 -6.9 -6.7 -6.7 -6.5 -6.4 -6.4 -6.3 -6.3 -6.3 -6.1 
CHEMBL450723 -6.9 -6.6 -6.5 -6.5 -6.5 -6.3 -6.3 -6.2 -6 -6 
CHEMBL470225 -6.9 -6.2 -6.2 -6 -6 -5.9 -5.9 -5.9 -5.9 -5.8 
CHEMBL474863 -6.9 -6.1 -6.1 -6 -5.9 -5.7 -5.6 -5.6 -5.6 -5.6 
CHEMBL481311 -6.9 -6.8 -6.6 -6.5 -6.5 -6.3 -6.2 -6.1 -6.1 -6.1 
CHEMBL493782 -6.9 -6.4 -6.2 -6.2 -6.2 -6.2 -6.2 -6.1 -6.1 -6.1 
CHEMBL496511 -6.9 -6.6 -6.4 -6.4 -6.3 -6.3 -6.2 -6.1 -6.1 -6.1 
CHEMBL515411 -6.9 -6.7 -6.7 -6.6 -6.4 -6.4 -6.3 -6.3 -6.2 -6.1 
CHEMBL565289 -6.9 -6.8 -6.7 -6.7 -6.5 -6.5 -6.4 -6.3 -6.3 -6.2 
CHEMBL574361 -6.9 -6.9 -6.4 -6 -6 -6 -6 -5.9 -5.9 -5.8 
CHEMBL598797 -6.9 -6.7 -6.4 -6.3 -6.1 -6 -5.9 -5.9 -5.7 -5.4 
CHEMBL1094158 -6.8 -6.7 -6.7 -6.6 -6.5 -6.5 -6.5 -6.5 -6.4 -6.4 
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CHEMBL1095764 -6.8 -6.8 -6.8 -6.7 -6.7 -6.7 -6.7 -6.5 -6.3 -6.3 
CHEMBL1630116 -6.8 -6.8 -6.7 -6.7 -6.7 -6.7 -6.6 -6.5 -6.3 -6.3 
CHEMBL1767038 -6.8 -6.3 -6.3 -6 -5.9 -5.9 -5.8 -5.8 -5.8 -5.8 
CHEMBL2047688 -6.8 -6.6 -6.5 -6.4 -6.4 -6.3 -6.2 -6.1 -6.1 -6 
CHEMBL2048755 -6.8 -6.6 -6.6 -6.6 -6.5 -6.5 -6.3 -6.2 -6.1 -6.1 
CHEMBL2158742 -6.8 -6.7 -6.6 -6.5 -6.5 -6.4 -6.4 -6.4 -6.3 -6.3 
CHEMBL2170186 -6.8 -6.5 -6.5 -6.4 -6.4 -6.3 -6.3 -6.3 -6.3 -6.3 
CHEMBL2179250 -6.8 -6.6 -6.5 -6.3 -6.2 -6.1 -6.1 -6.1 -6.1 -6.1 
CHEMBL2179617 -6.8 -6.5 -6.2 -6 -6 -5.9 -5.9 -5.7 -5.7 -5.7 
CHEMBL2204664 -6.8 -6.8 -6.8 -6.7 -6.6 -6.3 -6.3 -6.2 -6.2 -6.1 
CHEMBL2312164 -6.8 -6.7 -6.6 -6.6 -6.6 -6.5 -6.4 -6.4 -6.4 -6.4 
CHEMBL396097 -6.8 -6.6 -6.6 -6.6 -6.6 -6.6 -6.5 -6.5 -6.5 -6.5 
CHEMBL443241 -6.8 -6.7 -6.5 -6.5 -6.4 -6.4 -6.3 -6.1 -6.1 -6.1 
CHEMBL468841 -6.8 -6.7 -6.2 -6.1 -6 -5.9 -5.9 -5.9 -5.8 -5.8 
CHEMBL469134 -6.8 -6.6 -6.6 -6.4 -6.2 -6.2 -6.1 -6 -6 -6 
CHEMBL469275 -6.8 -6.7 -6.6 -6.6 -6.5 -6.5 -6.4 -6.4 -6.4 -6.3 
CHEMBL471173 -6.8 -6.4 -6.4 -5.9 -5.8 -5.8 -5.7 -5.5 -5.5 -5.4 
CHEMBL480973 -6.8 -6.7 -6.6 -6.6 -6.4 -6.3 -6.3 -6.2 -6.2 -6.2 
CHEMBL481018 -6.8 -6.7 -6.7 -6.5 -6.5 -6.4 -6.3 -6.3 -6.3 -6.3 
CHEMBL481319 -6.8 -6.6 -6.5 -6.5 -6.4 -6.3 -6.3 -6.3 -6 -6 
CHEMBL483893 -6.8 -6.4 -6.4 -6.4 -6.3 -6.2 -6.2 -6.2 -6 -5.9 
CHEMBL502752 -6.8 -6.5 -6.4 -6.3 -6.3 -6.3 -6.3 -6.3 -6.3 -6.2 
CHEMBL512516 -6.8 -6.8 -6.8 -6.1 -6 -5.9 -5.7 -5.7 -5.6 -5.5 
CHEMBL515285 -6.8 -6 -6 -5.9 -5.9 -5.8 -5.8 -5.7 -5.6 -5.6 
CHEMBL515452 -6.8 -6.7 -6.5 -6.4 -6.3 -6.3 -6.2 -6.2 -6.2 -6.1 
CHEMBL516399 -6.8 -5.9 -5.8 -5.8 -5.7 -5.7 -5.7 -5.7 -5.6 -5.5 
CHEMBL521431 -6.8 -6.8 -6.7 -6.7 -6.7 -6.7 -6.6 -6.6 -6.5 -6.5 
CHEMBL568151 -6.8 -6.4 -6.4 -6.3 -6.2 -6.1 -6 -6 -5.9 -5.9 
CHEMBL570806 -6.8 -6.2 -6.2 -6.2 -6.2 -6.1 -6.1 -6 -6 -6 
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CHEMBL589918 -6.8 -6.3 -6.2 -6.2 -6.1 -6.1 -6 -6 -6 -6 
CHEMBL1088735 -6.7 -6.6 -6.6 -6.5 -6.4 -6.4 -6.3 -6.3 -6.2 -6.2 
CHEMBL1098379 -6.7 -6.7 -6.4 -6.4 -6.2 -6.1 -6.1 -6 -5.9 -5.9 
CHEMBL1163778 -6.7 -6.5 -6.4 -6.4 -6.3 -6 -6 -5.9 -5.9 -5.9 
CHEMBL1164227 -6.7 -6.2 -6.2 -6.1 -6.1 -6.1 -5.9 -5.9 -5.8 -5.8 
CHEMBL1164992 -6.7 -6.6 -6.6 -6.1 -6.1 -6.1 -6 -5.9 -5.9 -5.9 
CHEMBL1469 -6.7 -6.4 -6.3 -6.1 -6 -5.9 -5.8 -5.8 -5.6 -5.5 
CHEMBL1631911 -6.7 -6.6 -6.6 -6.6 -6.5 -6.4 -6.4 -6.3 -6.3 -6.2 
CHEMBL1631916 -6.7 -6.7 -6.6 -6.5 -6.2 -6.2 -6.2 -5.9 -5.7 -5.7 
CHEMBL1767032 -6.7 -6.3 -6.3 -6.2 -6.2 -6.1 -6.1 -6.1 -6 -6 
CHEMBL1798001 -6.7 -6.7 -6.5 -6.5 -6.3 -6.3 -6.3 -6.3 -6.1 -6.1 
CHEMBL1800248 -6.7 -6.2 -6.1 -6.1 -6.1 -6.1 -5.9 -5.9 -5.8 -5.8 
CHEMBL1800374 -6.7 -6.7 -6.7 -6.6 -6.4 -6.3 -6.3 -6 -6 -5.8 
CHEMBL1835671 -6.7 -6.5 -6.4 -6.3 -6.2 -6.1 -6.1 -6 -6 -5.9 
CHEMBL2012812 -6.7 -6.2 -5.6 -5.6 -5.5 -5.5 -5.4 -5.4 -5.4 -5.3 
CHEMBL2018443 -6.7 -6.5 -5.9 -5.9 -5.8 -5.5 -5.4 -5.3 -5.2 -5.1 
CHEMBL2046621 -6.7 -6.2 -6.1 -6.1 -5.9 -5.8 -5.8 -5.7 -5.7 -5.6 
CHEMBL2047687 -6.7 -6.7 -6.5 -6.4 -6.3 -6.2 -6.1 -6.1 -6.1 -6 
CHEMBL2063395 -6.7 -6.5 -6.4 -6.4 -6.3 -6.2 -6.2 -6 -6 -6 
CHEMBL209551 -6.7 -6.1 -6.1 -6 -6 -6 -5.9 -5.9 -5.9 -5.8 
CHEMBL2333340 -6.7 -6.5 -6.4 -6.4 -6.3 -6.1 -6.1 -6.1 -6 -5.9 
CHEMBL238829 -6.7 -6.6 -6.6 -6.5 -6.5 -6.3 -6.3 -6.2 -6.2 -6 
CHEMBL269935 -6.7 -6.6 -6.3 -6.3 -6.2 -6.2 -6.1 -6.1 -6.1 -6 
CHEMBL270224 -6.7 -6.6 -6.6 -6.5 -6.3 -6.3 -6.3 -6.3 -6.2 -6.2 
CHEMBL402727 -6.7 -6.6 -6.6 -6.4 -6.4 -6.4 -6.2 -6.2 -6.1 -6 
CHEMBL471344 -6.7 -6.7 -6.7 -6.6 -6.6 -6.6 -6.6 -6.5 -6.5 -6.5 
CHEMBL475042 -6.7 -6.5 -6.5 -6.5 -6.3 -6.3 -6.3 -6.1 -6 -6 
CHEMBL479611 -6.7 -6.6 -6.5 -6.5 -6.3 -6.2 -6.2 -6.2 -6.2 -6.2 
CHEMBL479842 -6.7 -6.5 -6.3 -6.3 -6.2 -6.1 -6.1 -6 -6 -6 
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CHEMBL482096 -6.7 -6.6 -6.5 -6.1 -6 -6 -6 -6 -5.9 -5.9 
CHEMBL482136 -6.7 -6.6 -6.4 -6.1 -6.1 -6.1 -5.9 -5.9 -5.9 -5.7 
CHEMBL487370 -6.7 -6.5 -6.4 -6.4 -6.1 -6.1 -6.1 -6.1 -6 -6 
CHEMBL487741 -6.7 -6.4 -6.3 -6.3 -6.1 -6 -5.9 -5.9 -5.9 -5.9 
CHEMBL487943 -6.7 -6.7 -6.6 -6.4 -6.4 -6.1 -6.1 -6.1 -6.1 -6 
CHEMBL492956 -6.7 -6.6 -6.5 -6.4 -6.3 -6.2 -6.1 -6 -6 -5.9 
CHEMBL514671 -6.7 -6 -5.9 -5.9 -5.6 -5.5 -5.4 -5.3 -5.3 -5.2 
CHEMBL519491 -6.7 -6.5 -6.3 -6.1 -6.1 -6.1 -6 -6 -6 -5.9 
CHEMBL520056 -6.7 -6.7 -6.5 -6.4 -6.4 -6.2 -6.2 -6.1 -6.1 -6.1 
CHEMBL564382 -6.7 -6.7 -6.6 -6.5 -6.5 -6.5 -6.5 -6.5 -6.5 -6.4 
CHEMBL567457 -6.7 -6.6 -6.5 -6.4 -6.4 -6.3 -6.3 -6.3 -6.2 -6.1 
CHEMBL1094085 -6.6 -5.4 -5.4 -5.4 -5.4 -5.2 -5.1 -5.1 -5 -4.9 
CHEMBL1094159 -6.6 -6.1 -6.1 -5.9 -5.9 -5.8 -5.8 -5.7 -5.7 -5.7 
CHEMBL1094648 -6.6 -6.4 -6.4 -6.4 -6.4 -6.3 -6.3 -6.3 -6.2 -6.2 
CHEMBL1214759 -6.6 -6.4 -5.8 -5.8 -5.8 -5.7 -5.7 -5.6 -5.6 -5.6 
CHEMBL1767044 -6.6 -6.6 -6.6 -6.5 -6.3 -6.3 -6.2 -6.1 -6.1 -6.1 
CHEMBL1798004 -6.6 -6.6 -6.6 -6.4 -6.2 -6.1 -6.1 -6 -6 -6 
CHEMBL1800373 -6.6 -6.5 -6.5 -6.4 -6.3 -6.3 -6.2 -6.2 -6.2 -5.9 
CHEMBL1812334 -6.6 -6.1 -6.1 -6.1 -6.1 -6 -6 -6 -5.9 -5.9 
CHEMBL1914702 -6.6 -6.2 -6.2 -6.1 -5.9 -5.8 -5.8 -5.8 -5.7 -5.7 
CHEMBL2018298 -6.6 -6.5 -6.5 -6.2 -6.1 -6 -6 -6 -6 -5.9 
CHEMBL2018303 -6.6 -6.5 -6.4 -6.2 -6 -6 -5.9 -5.9 -5.9 -5.8 
CHEMBL2018452 -6.6 -6.4 -6.4 -6.4 -6.3 -6.2 -6.1 -6 -6 -6 
CHEMBL2047672 -6.6 -6.5 -6.4 -6.4 -6.2 -6.1 -6 -6 -5.9 -5.9 
CHEMBL2047677 -6.6 -6.6 -6.3 -6.2 -6.2 -6.1 -6.1 -6.1 -6 -6 
CHEMBL2047704 -6.6 -6.5 -6.5 -6.4 -6.4 -6.3 -6.3 -6.3 -6.2 -6.1 
CHEMBL2153072 -6.6 -6.5 -6.4 -6.3 -6.2 -6.2 -6.1 -6 -6 -6 
CHEMBL2153079 -6.6 -6.6 -6.5 -6.2 -6.2 -6.1 -6 -6 -5.9 -5.8 
CHEMBL227118 -6.6 -6 -5.7 -5.7 -5.6 -5.5 -5.3 -5.2 -5.1 -5.1 
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CHEMBL2333346 -6.6 -6.4 -6.2 -6.1 -6.1 -6 -6 -6 -5.9 -5.9 
CHEMBL2347006 -6.6 -6.6 -6.6 -6.6 -6.4 -6.3 -6.2 -6.2 -6.1 -6.1 
CHEMBL2347007 -6.6 -6.5 -6.5 -6.5 -6.5 -6.5 -6.4 -6.4 -6.4 -6.4 
CHEMBL242039 -6.6 -6.6 -6.4 -6.4 -6.3 -6.3 -6.2 -6.2 -6.1 -5.9 
CHEMBL247654 -6.6 -6.4 -6.4 -6.2 -5.9 -5.8 -5.7 -5.4 -5.4 -5.4 
CHEMBL272401 -6.6 -6.5 -6.4 -6.3 -6.2 -6.2 -6.2 -6.1 -6.1 -6.1 
CHEMBL360194 -6.6 -6.6 -6.6 -6.5 -6.4 -6.4 -6.3 -6.2 -6.2 -6.2 
CHEMBL399494 -6.6 -6.5 -6.4 -6.3 -6.2 -6.1 -6.1 -6 -6 -5.9 
CHEMBL427510 -6.6 -6.3 -6.1 -5.9 -5.8 -5.8 -5.7 -5.7 -5.6 -5.6 
CHEMBL470470 -6.6 -6.5 -6.4 -6.2 -6.2 -6.1 -6 -5.9 -5.9 -5.8 
CHEMBL472631 -6.6 -6.5 -6.3 -6.2 -6.1 -6.1 -5.9 -5.9 -5.9 -5.8 
CHEMBL473082 -6.6 -6.5 -6.5 -6.4 -6.3 -6.3 -6.3 -6.3 -6.3 -6.3 
CHEMBL473890 -6.6 -6.4 -6.3 -6.2 -6.1 -6 -5.8 -5.8 -5.7 -5.7 
CHEMBL479786 -6.6 -6.3 -6.1 -6 -5.9 -5.9 -5.9 -5.8 -5.8 -5.8 
CHEMBL481131 -6.6 -6.4 -6.2 -6.1 -6.1 -6 -5.9 -5.9 -5.8 -5.7 
CHEMBL482094 -6.6 -6.6 -6.5 -6.3 -6.3 -6.2 -6.1 -6.1 -5.8 -5.7 
CHEMBL482271 -6.6 -6.5 -6.5 -6.4 -6.4 -6.4 -6.4 -6.4 -6.3 -6.3 
CHEMBL482281 -6.6 -6.6 -6.1 -6.1 -6 -6 -6 -5.8 -5.8 -5.7 
CHEMBL485968 -6.6 -6.5 -6.5 -6.4 -6.4 -6.2 -6.1 -6.1 -5.7 -5.7 
CHEMBL488747 -6.6 -6.3 -6.2 -6.1 -6 -6 -6 -6 -6 -5.9 
CHEMBL497332 -6.6 -6.3 -6.2 -6.1 -6 -5.9 -5.7 -5.7 -5.7 -5.6 
CHEMBL509445 -6.6 -6.5 -6.4 -6.4 -6.3 -6.3 -6.1 -6.1 -6.1 -6 
CHEMBL513160 -6.6 -6.3 -6.2 -6.1 -6.1 -6.1 -6 -5.8 -5.8 -5.8 
CHEMBL520781 -6.6 -6.3 -6.2 -6 -6 -5.9 -5.9 -5.8 -5.7 -5.7 
CHEMBL523684 -6.6 -6.3 -6.3 -6.1 -6.1 -6.1 -6 -5.8 -5.8 -5.8 
CHEMBL524024 -6.6 -6.3 -6.2 -6.1 -6.1 -6 -5.9 -5.9 -5.8 -5.8 
CHEMBL568955 -6.6 -6.6 -6.4 -6.3 -6.3 -6.3 -6.3 -6.3 -6.2 -6.1 
CHEMBL569192 -6.6 -6.6 -6.4 -6.4 -6.3 -6.2 -6 -5.9 -5.8 -5.8 
CHEMBL592719 -6.6 -6.5 -6.4 -6.4 -6.4 -6.4 -6.2 -6.1 -6.1 -6 
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CHEMBL1095135 -6.5 -6.4 -6.3 -6.1 -6.1 -6 -5.9 -5.9 -5.8 -5.8 
CHEMBL1095450 -6.5 -5.8 -5.5 -5.5 -5.2 -5.1 -4.9 -4.6 -4.5 -4.4 
CHEMBL1096982 -6.5 -6 -5.9 -5.9 -5.8 -5.8 -5.8 -5.8 -5.7 -5.7 
CHEMBL1214762 -6.5 -6.4 -6.3 -6.2 -6.1 -6.1 -6 -5.9 -5.9 -5.8 
CHEMBL156887 -6.5 -6.4 -6 -5.7 -5.7 -5.6 -5.6 -5.6 -5.5 -5.5 
CHEMBL1631917 -6.5 -6.4 -6.4 -6.1 -5.7 -5.5 -5.4 -5.2 -5.2 -4.9 
CHEMBL1668018 -6.5 -6.5 -6.4 -6.3 -6.3 -6.3 -6.3 -6.2 -6.1 -6.1 
CHEMBL1767029 -6.5 -6.3 -6 -5.8 -5.6 -5.5 -5.4 -5.4 -5.3 -5.3 
CHEMBL1800247 -6.5 -6.4 -6.4 -6.3 -6.3 -6.2 -6.2 -6.1 -6.1 -6.1 
CHEMBL1801250 -6.5 -5.9 -5.8 -5.7 -5.7 -5.7 -5.7 -5.7 -5.6 -5.6 
CHEMBL2012811 -6.5 -6.5 -6.3 -6.3 -6.2 -6.2 -6.2 -6.2 -6.2 -6.1 
CHEMBL2018441 -6.5 -6.3 -6.3 -6.2 -5.9 -5.9 -5.9 -5.8 -5.7 -5.7 
CHEMBL2018442 -6.5 -6.1 -6 -6 -6 -6 -5.9 -5.9 -5.9 -5.9 
CHEMBL2047701 -6.5 -6.4 -6.3 -6.3 -6.2 -6.2 -6.2 -6 -6 -6 
CHEMBL2153070 -6.5 -6.4 -6.4 -6.2 -6 -5.8 -5.8 -5.7 -5.7 -5.7 
CHEMBL2153073 -6.5 -6.5 -6.4 -6.4 -6.4 -6.4 -6.3 -6.3 -6.3 -6.3 
CHEMBL227170 -6.5 -6.2 -6.2 -6.1 -6.1 -6 -5.9 -5.9 -5.8 -5.8 
CHEMBL2312168 -6.5 -6.5 -6.5 -6.3 -6.2 -6.1 -6 -6 -5.9 -5.9 
CHEMBL235210 -6.5 -6 -6 -6 -5.9 -5.9 -5.9 -5.8 -5.8 -5.8 
CHEMBL255805 -6.5 -5.8 -5.6 -5.5 -5.4 -5.4 -5.4 -5.3 -5.3 -5.3 
CHEMBL259434 -6.5 -6.1 -5.9 -5.9 -5.9 -5.8 -5.8 -5.8 -5.8 -5.7 
CHEMBL406734 -6.5 -6.5 -6.3 -6.3 -6.3 -6.2 -6.1 -6.1 -6.1 -6 
CHEMBL445518 -6.5 -6.3 -6.3 -6.3 -6.3 -6.2 -6 -5.9 -5.9 -5.8 
CHEMBL446512 -6.5 -6.1 -6.1 -6 -6 -5.9 -5.8 -5.8 -5.7 -5.7 
CHEMBL462146 -6.5 -6.4 -6.3 -6.3 -6.2 -6.1 -6.1 -6.1 -6 -5.9 
CHEMBL468513 -6.5 -6.5 -6.5 -6.5 -6.4 -6.4 -6.4 -6.4 -6.3 -6.3 
CHEMBL474046 -6.5 -6.2 -6.2 -5.8 -5.7 -5.6 -5.6 -5.5 -5.5 -5.5 
CHEMBL493749 -6.5 -5.8 -5.6 -5.6 -5.5 -5.5 -5.5 -5.4 -5.4 -5.4 
CHEMBL514478 -6.5 -6.4 -6.1 -6.1 -6 -6 -6 -5.7 -5.6 -5.5 
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CHEMBL566824 -6.5 -6.4 -6.3 -6.2 -6.1 -5.9 -5.9 -5.6 -5.4 -5.3 
CHEMBL570041 -6.5 -6.3 -6.3 -6.3 -6.1 -6.1 -6.1 -6 -6 -6 
CHEMBL585939 -6.5 -6.2 -6.2 -6.1 -6.1 -6.1 -6 -5.9 -5.8 -5.8 
CHEMBL609583 -6.5 -5.5 -5.4 -5.4 -5.3 -5.1 -5 -5 -5 -4.9 
CHEMBL96051 -6.5 -6.3 -6.2 -6.1 -5.9 -5.9 -5.8 -5.7 -5.7 -5.7 
CHEMBL1093335 -6.4 -6.4 -6.1 -6.1 -6 -5.8 -5.7 -5.7 -5.7 -5.7 
CHEMBL1095124 -6.4 -5.9 -5.9 -5.9 -5.7 -5.7 -5.6 -5.6 -5.5 -5.5 
CHEMBL1096034 -6.4 -6.1 -6 -6 -6 -5.9 -5.9 -5.8 -5.8 -5.7 
CHEMBL1096985 -6.4 -6.4 -6.3 -6.2 -6.2 -6 -6 -5.9 -5.9 -5.9 
CHEMBL1165164 -6.4 -6.3 -6.2 -6.2 -6.2 -6.1 -6.1 -6 -6 -6 
CHEMBL138090 -6.4 -6 -5.9 -5.9 -5.8 -5.8 -5.7 -5.6 -5.6 -5.6 
CHEMBL1630109 -6.4 -6.4 -6.2 -6.1 -5.9 -5.9 -5.8 -5.8 -5.7 -5.7 
CHEMBL1767035 -6.4 -6.3 -6.2 -6.1 -6.1 -6 -6 -5.9 -5.8 -5.8 
CHEMBL1767037 -6.4 -6.3 -6.2 -6.2 -6.1 -5.9 -5.8 -5.7 -5.7 -5.6 
CHEMBL1798006 -6.4 -6.2 -6.1 -5.9 -5.8 -5.8 -5.8 -5.7 -5.6 -5.6 
CHEMBL1808674 -6.4 -6.1 -5.9 -5.8 -5.7 -5.7 -5.6 -5.5 -5.5 -5.5 
CHEMBL2018295 -6.4 -6.1 -6.1 -6 -5.9 -5.9 -5.9 -5.8 -5.8 -5.8 
CHEMBL2046608 -6.4 -6.4 -6.3 -6.3 -6.1 -6.1 -6.1 -5.9 -5.9 -5.9 
CHEMBL2046615 -6.4 -6.3 -6.3 -6.3 -6.1 -6.1 -6 -5.9 -5.9 -5.9 
CHEMBL2153076 -6.4 -6.3 -6.1 -6 -6 -5.9 -5.9 -5.9 -5.8 -5.8 
CHEMBL2178345 -6.4 -6 -5.9 -5.8 -5.8 -5.7 -5.7 -5.7 -5.6 -5.6 
CHEMBL2337869 -6.4 -6.1 -5.9 -5.9 -5.9 -5.8 -5.7 -5.7 -5.7 -5.6 
CHEMBL243997 -6.4 -6.4 -6.2 -6.2 -6.2 -6.1 -6.1 -6.1 -6.1 -6 
CHEMBL402363 -6.4 -5.9 -5.7 -5.7 -5.6 -5.6 -5.5 -5.5 -5.5 -5.4 
CHEMBL474097 -6.4 -6.4 -6.2 -6.2 -6.1 -6.1 -6 -5.9 -5.9 -5.9 
CHEMBL475861 -6.4 -6.3 -6.2 -6.1 -5.8 -5.8 -5.6 -5.6 -5.5 -5.4 
CHEMBL479970 -6.4 -6.3 -6.2 -6.2 -6.2 -6.1 -6.1 -6.1 -6 -6 
CHEMBL479971 -6.4 -6 -5.6 -5.6 -5.6 -5.6 -5.4 -5.4 -5.3 -5.3 
CHEMBL487107 -6.4 -6.3 -5.7 -5.5 -5.4 -5.4 -5.4 -5.4 -5.4 -5.3 
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CHEMBL487615 -6.4 -6.3 -5.9 -5.8 -5.8 -5.7 -5.7 -5.7 -5.6 -5.4 
CHEMBL493347 -6.4 -6.4 -6.3 -6.2 -6.1 -6.1 -6.1 -6.1 -6.1 -6 
CHEMBL493872 -6.4 -6.3 -6.3 -6.3 -6.3 -6.2 -6.2 -6.2 -6.1 -6 
CHEMBL494331 -6.4 -5.9 -5.8 -5.3 -5.1 -5.1 -5 -5 -5 -4.9 
CHEMBL511715 -6.4 -6.2 -6.2 -6 -6 -5.9 -5.7 -5.7 -5.6 -5.6 
CHEMBL511749 -6.4 -6.2 -6.2 -6.1 -6.1 -6.1 -6.1 -6.1 -6 -6 
CHEMBL524193 -6.4 -6.3 -6.2 -6.2 -6 -5.9 -5.9 -5.8 -5.8 -5.7 
CHEMBL1091475 -6.3 -6.2 -6.1 -6.1 -6 -6 -6 -5.8 -5.8 -5.8 
CHEMBL1094710 -6.3 -6.1 -5.7 -5.6 -5.4 -5.3 -5.2 -5.2 -5.1 -5.1 
CHEMBL1095119 -6.3 -6.2 -6.1 -6.1 -6.1 -6 -6 -6 -6 -5.9 
CHEMBL1095719 -6.3 -5.7 -5.6 -5.6 -5.5 -5.4 -5.3 -5.2 -5.1 -5 
CHEMBL1097981 -6.3 -6.2 -6.2 -6 -5.9 -5.7 -5.6 -5.6 -5.5 -5.5 
CHEMBL1098042 -6.3 -6.2 -6.2 -6.1 -6.1 -6.1 -6 -6 -5.9 -5.9 
CHEMBL115468 -6.3 -5.9 -5.9 -5.8 -5.7 -5.6 -5.5 -5.5 -5.5 -5.4 
CHEMBL1164226 -6.3 -6.3 -6.1 -6 -6 -6 -6 -5.9 -5.9 -5.9 
CHEMBL1243289 -6.3 -5.8 -5.6 -5.4 -5.2 -4.6 -4.5 -4.4 -4.4 -4.4 
CHEMBL1722433 -6.3 -6.2 -6.2 -5.8 -5.7 -5.7 -5.5 -5.4 -5.3 -5.2 
CHEMBL1800243 -6.3 -5.9 -5.9 -5.7 -5.7 -5.7 -5.6 -5.5 -5.5 -5.5 
CHEMBL180911 -6.3 -6.3 -6.1 -6 -6 -6 -6 -5.9 -5.9 -5.9 
CHEMBL2012818 -6.3 -6 -5.9 -5.9 -5.7 -5.6 -5.6 -5.6 -5.6 -5.5 
CHEMBL2018299 -6.3 -6.2 -6 -5.9 -5.9 -5.9 -5.8 -5.8 -5.7 -5.7 
CHEMBL2023529 -6.3 -6.2 -6.2 -6.1 -6 -5.9 -5.8 -5.8 -5.7 -5.7 
CHEMBL2023530 -6.3 -6.2 -5.8 -5.8 -5.7 -5.7 -5.6 -5.6 -5.6 -5.4 
CHEMBL2047673 -6.3 -6.1 -6 -6 -5.9 -5.9 -5.8 -5.8 -5.7 -5.7 
CHEMBL2047675 -6.3 -5.7 -5.6 -5.6 -5.5 -5.4 -5.4 -5.4 -5.3 -5.3 
CHEMBL2063396 -6.3 -6.2 -6 -6 -5.9 -5.8 -5.8 -5.8 -5.8 -5.8 
CHEMBL2093007 -6.3 -5.9 -5.9 -5.7 -5.7 -5.7 -5.5 -5.5 -5.4 -5.4 
CHEMBL2337862 -6.3 -5.9 -5.9 -5.7 -5.5 -5.4 -5.3 -5.3 -5.3 -5.2 
CHEMBL2337865 -6.3 -5.9 -5.7 -5.6 -5.6 -5.6 -5.6 -5.4 -5.4 -5.4 
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CHEMBL2337868 -6.3 -6.3 -6.3 -6.3 -6.3 -6.2 -6.1 -6.1 -6.1 -6.1 
CHEMBL235674 -6.3 -6.2 -6.1 -6.1 -6.1 -5.9 -5.9 -5.9 -5.8 -5.8 
CHEMBL255714 -6.3 -5.9 -5.8 -5.7 -5.7 -5.6 -5.6 -5.5 -5.5 -5.5 
CHEMBL337584 -6.3 -6.1 -6 -6 -5.9 -5.9 -5.8 -5.8 -5.8 -5.6 
CHEMBL389687 -6.3 -6.2 -6.1 -6.1 -6 -5.9 -5.9 -5.7 -5.6 -5.6 
CHEMBL437029 -6.3 -6 -6 -5.8 -5.7 -5.5 -5.5 -5.5 -5.5 -5.4 
CHEMBL474015 -6.3 -6.3 -6.2 -6.1 -6 -5.9 -5.8 -5.8 -5.7 -5.7 
CHEMBL481297 -6.3 -6.2 -6.1 -5.8 -5.8 -5.8 -5.8 -5.8 -5.8 -5.7 
CHEMBL483495 -6.3 -5.7 -5.6 -5.5 -5.4 -5.4 -5.4 -5.3 -5.3 -5.3 
CHEMBL485967 -6.3 -6.2 -6.1 -6 -5.9 -5.9 -5.6 -5.6 -5.6 -5.6 
CHEMBL511432 -6.3 -6.1 -6.1 -6.1 -5.8 -5.8 -5.8 -5.7 -5.7 -5.6 
CHEMBL519746 -6.3 -5.9 -5.8 -5.7 -5.6 -5.3 -5.3 -5.3 -5.2 -5.2 
CHEMBL568958 -6.3 -6.3 -6.1 -6 -6 -5.9 -5.9 -5.9 -5.7 -5.7 
CHEMBL598363 -6.3 -6 -6 -5.9 -5.9 -5.9 -5.8 -5.8 -5.7 -5.7 
CHEMBL1076939 -6.2 -6.1 -6.1 -5.7 -5.5 -5.4 -5.4 -5.2 -5.1 -5 
CHEMBL1088736 -6.2 -5.7 -5.6 -5.6 -5.5 -5.5 -5.5 -5.4 -5.4 -5.4 
CHEMBL1093033 -6.2 -6.1 -5.9 -5.5 -5.4 -5.4 -5.4 -5.3 -5.2 -5.1 
CHEMBL115011 -6.2 -6.1 -6 -5.9 -5.9 -5.9 -5.8 -5.7 -5.6 -5.6 
CHEMBL1165293 -6.2 -6.1 -6 -5.9 -5.8 -5.8 -5.8 -5.7 -5.7 -5.6 
CHEMBL1798007 -6.2 -6.2 -5.8 -5.5 -5.5 -5.4 -5.3 -5.3 -5.3 -5.2 
CHEMBL2018302 -6.2 -5.8 -5.7 -5.7 -5.7 -5.5 -5.4 -5.4 -5.3 -5.2 
CHEMBL2023528 -6.2 -5.8 -5.7 -5.7 -5.6 -5.5 -5.5 -5.5 -5.4 -5.4 
CHEMBL2047678 -6.2 -6.2 -6.1 -6.1 -5.9 -5.8 -5.8 -5.8 -5.8 -5.8 
CHEMBL2179246 -6.2 -6 -6 -6 -5.9 -5.7 -5.7 -5.7 -5.6 -5.6 
CHEMBL2179249 -6.2 -6.2 -6.1 -5.9 -5.7 -5.7 -5.6 -5.6 -5.6 -5.5 
CHEMBL2179619 -6.2 -6.1 -6.1 -6 -5.9 -5.9 -5.9 -5.9 -5.9 -5.8 
CHEMBL236678 -6.2 -6 -5.7 -5.7 -5.7 -5.6 -5.6 -5.6 -5.6 -5.5 
CHEMBL247217 -6.2 -5.8 -5.6 -5.5 -5.5 -5.5 -5.4 -5.4 -5.4 -5.3 
CHEMBL253868 -6.2 -6.2 -6.2 -6.2 -6.1 -6.1 -6.1 -6.1 -6 -6 
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CHEMBL256440 -6.2 -6.1 -6.1 -6 -5.9 -5.9 -5.8 -5.8 -5.7 -5.7 
CHEMBL363750 -6.2 -6.1 -6 -6 -5.8 -5.7 -5.6 -5.6 -5.6 -5.5 
CHEMBL379049 -6.2 -6.2 -6.2 -5.7 -5.7 -5.5 -5.5 -5.3 -5.3 -5.3 
CHEMBL401837 -6.2 -6.2 -6 -6 -6 -5.9 -5.9 -5.9 -5.8 -5.8 
CHEMBL454438 -6.2 -6.2 -6.2 -6.1 -6 -5.9 -5.9 -5.9 -5.8 -5.7 
CHEMBL455735 -6.2 -5.9 -5.6 -5.6 -5.6 -5.5 -5.4 -5.3 -5.3 -5.2 
CHEMBL467678 -6.2 -6.1 -5.9 -5.7 -5.5 -5.5 -5.4 -5.4 -5.4 -5.3 
CHEMBL469274 -6.2 -6.2 -6 -5.9 -5.9 -5.7 -5.6 -5.6 -5.6 -5.6 
CHEMBL471044 -6.2 -5.9 -5.8 -5.7 -5.6 -5.6 -5.6 -5.6 -5.6 -5.6 
CHEMBL474001 -6.2 -5.5 -5.4 -5.4 -5.3 -5.2 -5.2 -5.2 -5.2 -5.2 
CHEMBL474446 -6.2 -5.9 -5.9 -5.9 -5.7 -5.7 -5.6 -5.5 -5.4 -5.4 
CHEMBL475101 -6.2 -5.8 -5.7 -5.5 -5.5 -5.4 -5.4 -5.4 -5.4 -5.3 
CHEMBL481136 -6.2 -6.1 -6.1 -5.9 -5.8 -5.7 -5.6 -5.6 -5.6 -5.5 
CHEMBL481148 -6.2 -6 -5.9 -5.9 -5.8 -5.7 -5.7 -5.7 -5.7 -5.6 
CHEMBL482765 -6.2 -6.1 -6 -5.8 -5.8 -5.8 -5.8 -5.8 -5.8 -5.7 
CHEMBL485514 -6.2 -6 -5.9 -5.9 -5.9 -5.8 -5.7 -5.7 -5.7 -5.7 
CHEMBL490067 -6.2 -6 -5.8 -5.6 -5.6 -5.6 -5.5 -5.4 -5.4 -5.4 
CHEMBL493785 -6.2 -6.1 -5.8 -5.8 -5.8 -5.7 -5.7 -5.7 -5.7 -5.6 
CHEMBL504040 -6.2 -5.7 -5.7 -5.6 -5.5 -5.2 -5.2 -5.2 -5.1 -5 
CHEMBL514351 -6.2 -6.1 -5.7 -5.7 -5.4 -5.4 -5.3 -5.3 -5.3 -5.2 
CHEMBL517997 -6.2 -5.9 -5.9 -5.7 -5.6 -5.6 -5.6 -5.6 -5.5 -5.4 
CHEMBL519739 -6.2 -6.2 -5.7 -5.7 -5.6 -5.6 -5.5 -5.5 -5.5 -5.5 
CHEMBL55895 -6.2 -5.9 -5.6 -5.6 -5.4 -5.4 -5.4 -5.4 -5.3 -5.2 
CHEMBL582926 -6.2 -6.1 -6.1 -6 -6 -6 -5.8 -5.7 -5.7 -5.6 
CHEMBL594544 -6.2 -5.9 -5.7 -5.7 -5.7 -5.6 -5.6 -5.5 -5.4 -5.4 
CHEMBL1095076 -6.1 -6.1 -6 -6 -5.9 -5.9 -5.8 -5.7 -5.6 -5.6 
CHEMBL1095118 -6.1 -6 -5.9 -5.9 -5.8 -5.8 -5.7 -5.7 -5.7 -5.6 
CHEMBL1095437 -6.1 -6 -6 -5.8 -5.8 -5.7 -5.6 -5.6 -5.6 -5.4 
CHEMBL1095765 -6.1 -5.9 -5.9 -5.9 -5.8 -5.7 -5.6 -5.4 -5.3 -5.3 
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CHEMBL1096432 -6.1 -5.9 -5.9 -5.9 -5.7 -5.6 -5.6 -5.6 -5.5 -5.4 
CHEMBL1097761 -6.1 -5.7 -5.5 -5.4 -5.4 -5.3 -5.2 -5.2 -5.1 -5 
CHEMBL1098067 -6.1 -5.7 -5.6 -5.6 -5.6 -5.5 -5.4 -5.4 -5.3 -5.3 
CHEMBL1164244 -6.1 -6.1 -6 -5.7 -5.7 -5.7 -5.6 -5.6 -5.5 -5.4 
CHEMBL1290142 -6.1 -6 -5.9 -5.9 -5.9 -5.7 -5.6 -5.6 -5.5 -5.5 
CHEMBL152665 -6.1 -5.9 -5.8 -5.7 -5.6 -5.5 -5.5 -5.5 -5.4 -5.3 
CHEMBL1672332 -6.1 -6 -5.8 -5.8 -5.7 -5.7 -5.7 -5.6 -5.6 -5.5 
CHEMBL1767040 -6.1 -5.7 -5.7 -5.6 -5.6 -5.5 -5.5 -5.4 -5.4 -5.3 
CHEMBL1798005 -6.1 -6 -6 -5.9 -5.9 -5.9 -5.8 -5.8 -5.7 -5.7 
CHEMBL1800375 -6.1 -6 -5.9 -5.9 -5.9 -5.8 -5.8 -5.7 -5.7 -5.7 
CHEMBL1822043 -6.1 -6 -5.8 -5.5 -5.4 -5.3 -5.1 -5.1 -5 -5 
CHEMBL2018450 -6.1 -6 -5.9 -5.9 -5.8 -5.8 -5.7 -5.6 -5.6 -5.5 
CHEMBL2046620 -6.1 -5.9 -5.7 -5.5 -5.4 -5.3 -5.3 -5.1 -5.1 -5.1 
CHEMBL2047669 -6.1 -5.8 -5.7 -5.7 -5.6 -5.6 -5.6 -5.5 -5.5 -5.5 
CHEMBL2047680 -6.1 -6.1 -5.6 -5.2 -5 -4.9 -4.9 -4.9 -4.9 -4.6 
CHEMBL2047690 -6.1 -5.7 -5.6 -5.2 -5.2 -5.1 -5.1 -5.1 -5.1 -5 
CHEMBL2153078 -6.1 -5.9 -5.7 -5.6 -5.4 -5.2 -5 -4.8 -4.6 -4.6 
CHEMBL2179244 -6.1 -5.8 -5.7 -5.7 -5.7 -5.6 -5.5 -5.5 -5.5 -5.5 
CHEMBL2179248 -6.1 -6 -5.8 -5.7 -5.6 -5.6 -5.5 -5.5 -5.5 -5.5 
CHEMBL471041 -6.1 -5.9 -5.9 -5.8 -5.8 -5.7 -5.6 -5.6 -5.5 -5.5 
CHEMBL473825 -6.1 -6.1 -6.1 -6.1 -6 -6 -5.9 -5.9 -5.8 -5.8 
CHEMBL475102 -6.1 -6.1 -5.8 -5.8 -5.8 -5.8 -5.8 -5.8 -5.8 -5.7 
CHEMBL475796 -6.1 -6 -5.9 -5.8 -5.8 -5.7 -5.7 -5.7 -5.6 -5.6 
CHEMBL482075 -6.1 -5.9 -5.7 -5.7 -5.7 -5.6 -5.6 -5.5 -5.4 -5.4 
CHEMBL482137 -6.1 -6.1 -6.1 -6 -6 -6 -5.9 -5.9 -5.8 -5.7 
CHEMBL483693 -6.1 -5.9 -5.8 -5.8 -5.7 -5.6 -5.5 -5.5 -5.4 -5.3 
CHEMBL487742 -6.1 -6 -5.9 -5.7 -5.7 -5.6 -5.6 -5.5 -5.5 -5.5 
CHEMBL497123 -6.1 -6.1 -5.6 -5.5 -5.5 -5.5 -5.5 -5.5 -5.5 -5.4 
CHEMBL519134 -6.1 -5.9 -5.9 -5.8 -5.7 -5.7 -5.6 -5.6 -5.5 -5.4 
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CHEMBL521355 -6.1 -5.9 -5.8 -5.7 -5.7 -5.6 -5.5 -5.5 -5.3 -5.3 
CHEMBL1091815 -6 -5.8 -5.6 -5.5 -5.5 -5.5 -5.4 -5.4 -5.3 -5.3 
CHEMBL1094794 -6 -5.9 -5.8 -5.8 -5.8 -5.5 -5.5 -5.4 -5.4 -5.3 
CHEMBL138626 -6 -5.9 -5.9 -5.8 -5.7 -5.7 -5.6 -5.6 -5.6 -5.5 
CHEMBL1630107 -6 -6 -5.7 -5.6 -5.6 -5.5 -5.5 -5.3 -5.3 -5.1 
CHEMBL1800241 -6 -6 -5.9 -5.9 -5.8 -5.8 -5.8 -5.7 -5.6 -5.6 
CHEMBL1822046 -6 -5.8 -5.7 -5.4 -5.2 -5 -5 -5 -4.9 -4.9 
CHEMBL1923808 -6 -6 -6 -5.8 -5.8 -5.7 -5.5 -5.5 -5.5 -5.5 
CHEMBL2012817 -6 -6 -6 -5.9 -5.7 -5.6 -5.5 -5.5 -5.4 -5.4 
CHEMBL2018296 -6 -5.9 -5.9 -5.7 -5.4 -5.4 -5.3 -5.3 -5.3 -5.2 
CHEMBL2018449 -6 -6 -5.9 -5.8 -5.8 -5.7 -5.7 -5.6 -5.6 -5.6 
CHEMBL2046611 -6 -6 -6 -6 -5.9 -5.9 -5.8 -5.8 -5.8 -5.8 
CHEMBL2047540 -6 -5.8 -5.7 -5.7 -5.6 -5.6 -5.5 -5.4 -5.4 -5.4 
CHEMBL2047689 -6 -5.9 -5.8 -5.7 -5.6 -5.6 -5.4 -5.4 -5.4 -5.3 
CHEMBL2047691 -6 -5.9 -5.7 -5.7 -5.7 -5.6 -5.5 -5.5 -5.4 -5.4 
CHEMBL2047696 -6 -5.9 -5.8 -5.8 -5.7 -5.7 -5.7 -5.7 -5.7 -5.7 
CHEMBL2153077 -6 -6 -6 -6 -5.9 -5.9 -5.8 -5.7 -5.7 -5.5 
CHEMBL2178344 -6 -5.4 -5.3 -5 -5 -4.8 -4.8 -4.7 -4.6 -4.6 
CHEMBL2333338 -6 -5.9 -5.9 -5.9 -5.8 -5.7 -5.5 -5.5 -5.4 -5.4 
CHEMBL409526 -6 -5.9 -5.9 -5.9 -5.9 -5.8 -5.8 -5.7 -5.7 -5.7 
CHEMBL455455 -6 -5.7 -5.7 -5.7 -5.5 -5.5 -5.5 -5.4 -5.3 -5.2 
CHEMBL462209 -6 -5.4 -5.2 -4.9 -4.6 -4.5 -4.5 -4.3 -4.3 -4.1 
CHEMBL470843 -6 -5.7 -5.5 -5.5 -5.4 -5.3 -5.3 -5.3 -5.2 -5.2 
CHEMBL475307 -6 -5.8 -5.8 -5.7 -5.5 -5.5 -5.5 -5.5 -5.4 -5.4 
CHEMBL481955 -6 -5.9 -5.9 -5.9 -5.9 -5.8 -5.7 -5.7 -5.7 -5.5 
CHEMBL482270 -6 -6 -6 -6 -5.9 -5.9 -5.9 -5.7 -5.6 -5.6 
CHEMBL512043 -6 -5.9 -5.8 -5.8 -5.7 -5.7 -5.6 -5.6 -5.6 -5.6 
CHEMBL512644 -6 -5.9 -5.7 -5.7 -5.7 -5.7 -5.6 -5.6 -5.5 -5.5 
CHEMBL515258 -6 -5.9 -5.8 -5.7 -5.7 -5.7 -5.7 -5.6 -5.6 -5.5 
53 
 
CHEMBL516218 -6 -5.7 -5.5 -5.5 -5.5 -5.4 -5.3 -5.2 -5.2 -5.1 
CHEMBL569447 -6 -5.9 -5.8 -5.8 -5.7 -5.5 -5.5 -5.3 -5.3 -5.3 
CHEMBL569946 -6 -5.7 -5.7 -5.7 -5.6 -5.5 -5.5 -5.3 -5.3 -5.3 
CHEMBL941 -6 -5.7 -5.4 -5.4 -5.4 -5.3 -5.3 -5.3 -5.2 -5.2 
CHEMBL1164212 -5.9 -5.8 -5.7 -5.7 -5.7 -5.7 -5.3 -5.3 -5.3 -5.3 
CHEMBL1767042 -5.9 -5.9 -5.8 -5.7 -5.6 -5.6 -5.5 -5.4 -5.4 -5.3 
CHEMBL1800242 -5.9 -5.9 -5.8 -5.6 -5.6 -5.5 -5.5 -5.4 -5.4 -5.3 
CHEMBL1800384 -5.9 -5.9 -5.9 -5.9 -5.8 -5.8 -5.8 -5.7 -5.7 -5.7 
CHEMBL2012813 -5.9 -5.7 -5.6 -5.6 -5.6 -5.3 -5.3 -5.3 -5.2 -5.2 
CHEMBL2048746 -5.9 -5.9 -5.8 -5.7 -5.7 -5.6 -5.5 -5.4 -5.4 -5.4 
CHEMBL2178342 -5.9 -5.9 -5.8 -5.7 -5.6 -5.3 -5.2 -5.2 -5.1 -4.9 
CHEMBL2179247 -5.9 -5.9 -5.7 -5.7 -5.7 -5.5 -5.5 -5.5 -5.4 -5.4 
CHEMBL235300 -5.9 -5.7 -5.6 -5.6 -5.5 -5.3 -5.2 -5.2 -5.1 -5.1 
CHEMBL253308 -5.9 -5.7 -5.6 -5.5 -5.5 -5.2 -5.2 -5.2 -5.2 -5.2 
CHEMBL257972 -5.9 -5.9 -5.7 -5.6 -5.6 -5.5 -5.5 -5.5 -5.5 -5.4 
CHEMBL356066 -5.9 -5.7 -5.4 -5.4 -5.3 -5.2 -5.1 -5.1 -5.1 -5.1 
CHEMBL388710 -5.9 -5.7 -5.6 -5.5 -5.5 -5.5 -5.5 -5.5 -5.5 -5.4 
CHEMBL461333 -5.9 -5.8 -5.7 -5.6 -5.6 -5.6 -5.5 -5.5 -5.5 -5.4 
CHEMBL462223 -5.9 -5.8 -5.8 -5.7 -5.7 -5.7 -5.6 -5.6 -5.6 -5.6 
CHEMBL467793 -5.9 -5.9 -5.8 -5.8 -5.5 -5.4 -5.4 -5.4 -5.3 -5.3 
CHEMBL481538 -5.9 -5.7 -5.7 -5.7 -5.6 -5.6 -5.5 -5.5 -5.5 -5.4 
CHEMBL483892 -5.9 -5.3 -5.2 -5.2 -5.2 -5.2 -5.1 -5 -5 -5 
CHEMBL494138 -5.9 -5.9 -5.9 -5.9 -5.9 -5.8 -5.8 -5.8 -5.7 -5.7 
CHEMBL514485 -5.9 -5.8 -5.6 -5.6 -5.5 -5.4 -5.4 -5.3 -5.3 -5.2 
CHEMBL519738 -5.9 -5.9 -5.7 -5.5 -5.4 -5.1 -5.1 -5 -4.9 -4.7 
CHEMBL566817 -5.9 -5.6 -4.6 -4.6 -4.4 -4.3 -4.1 -4.1 -3.9 -3.9 
CHEMBL569288 -5.9 -5.6 -5.5 -5.4 -5.4 -5.4 -5.3 -5.3 -5.1 -5.1 
CHEMBL570589 -5.9 -5.7 -5.6 -5.5 -5.4 -5.1 -5 -4.9 -4.9 -4.8 
CHEMBL572044 -5.9 -5.8 -5.7 -5.7 -5.7 -5.7 -5.7 -5.5 -5.5 -5.5 
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CHEMBL589906 -5.9 -5.8 -5.7 -5.7 -5.7 -5.6 -5.6 -5.5 -5.5 -5.5 
CHEMBL109 -5.8 -5.4 -5.4 -5.3 -5.3 -5.1 -5 -5 -5 -4.9 
CHEMBL1096433 -5.8 -5.7 -5.5 -5.2 -5 -4.9 -4.8 -4.8 -4.7 -4.7 
CHEMBL1099096 -5.8 -5.7 -5.7 -5.6 -5.5 -5.5 -5.4 -5.4 -5.4 -5.4 
CHEMBL154517 -5.8 -5.7 -5.6 -5.6 -5.6 -5.6 -5.5 -5.5 -5.5 -5.5 
CHEMBL1630114 -5.8 -5.7 -5.6 -5.6 -5.6 -5.5 -5.4 -5.4 -5.4 -5.3 
CHEMBL1631918 -5.8 -5.4 -5.4 -5.1 -4.9 -4.9 -4.8 -4.7 -4.7 -4.7 
CHEMBL1767034 -5.8 -5.7 -5.7 -5.6 -5.5 -5.5 -5.5 -5.5 -5.5 -5.4 
CHEMBL1767043 -5.8 -5.7 -5.7 -5.7 -5.7 -5.6 -5.5 -5.5 -5.4 -5.3 
CHEMBL178456 -5.8 -5.4 -5.3 -5.2 -5.1 -5 -5 -5 -4.9 -4.9 
CHEMBL1798008 -5.8 -5.8 -5.7 -5.6 -5.5 -5.5 -5.4 -5.4 -5.3 -5.3 
CHEMBL1800250 -5.8 -5.5 -5.4 -5.4 -5.4 -5.3 -5.3 -5.3 -5.3 -5.2 
CHEMBL1800378 -5.8 -5.8 -5.7 -5.7 -5.7 -5.5 -5.4 -5.4 -5.4 -5.4 
CHEMBL1822050 -5.8 -5.6 -5.5 -5.5 -5.4 -5.4 -5.3 -5.3 -5.2 -5.2 
CHEMBL2046612 -5.8 -5.6 -5.5 -5.5 -5.5 -5.4 -5.4 -5.4 -5.3 -5.3 
CHEMBL2047682 -5.8 -5.7 -5.7 -5.7 -5.6 -5.6 -5.5 -5.5 -5.4 -5.4 
CHEMBL2179615 -5.8 -5.8 -5.6 -5.4 -5.3 -5.1 -5 -4.8 -4.8 -4.7 
CHEMBL2336043 -5.8 -5.8 -5.7 -5.7 -5.5 -5.5 -5.5 -5.4 -5.3 -5.2 
CHEMBL2347010 -5.8 -5.8 -5.7 -5.6 -5.6 -5.5 -5.5 -5.4 -5.4 -5.3 
CHEMBL242473 -5.8 -5.6 -5.5 -5.5 -5.5 -5.5 -5.3 -5.2 -5.2 -5.2 
CHEMBL387924 -5.8 -5.3 -5.2 -5.1 -5.1 -5 -4.9 -4.9 -4.8 -4.8 
CHEMBL393361 -5.8 -5.4 -5.4 -5.4 -5.3 -5.3 -5.1 -5 -5 -5 
CHEMBL467792 -5.8 -5.5 -5.5 -5.4 -5.4 -5.4 -5.3 -5.3 -5 -5 
CHEMBL475043 -5.8 -5.4 -5.4 -5.4 -5.3 -5.2 -5.1 -5.1 -5 -4.9 
CHEMBL475862 -5.8 -5.6 -5.5 -5.5 -5.5 -5.5 -5.4 -5.4 -5.4 -5.3 
CHEMBL482272 -5.8 -5.7 -5.6 -5.6 -5.5 -5.4 -5.4 -5.4 -5.3 -5.3 
CHEMBL485771 -5.8 -5.5 -5.3 -5.3 -5.2 -5.2 -5.2 -5 -5 -5 
CHEMBL487347 -5.8 -5.8 -5.5 -5.4 -5.4 -5.4 -5.2 -5.2 -5.2 -5.1 
CHEMBL493249 -5.8 -5.8 -5.8 -5.6 -5.6 -5.6 -5.3 -5.3 -5.2 -5.2 
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CHEMBL494124 -5.8 -5.7 -5.6 -5.6 -5.5 -5.5 -5.4 -5.4 -5.3 -5.3 
CHEMBL509207 -5.8 -5.6 -5.6 -5.6 -5.5 -5.5 -5.5 -5.5 -5.4 -5.3 
CHEMBL515295 -5.8 -5.8 -5.7 -5.6 -5.5 -5.4 -5.3 -5.2 -5.2 -5.2 
CHEMBL517869 -5.8 -5.6 -5.5 -5.5 -5.5 -5.4 -5.4 -5.4 -5.3 -5.3 
CHEMBL1094094 -5.7 -5.5 -5.5 -5.3 -5.3 -5.3 -5.3 -5.2 -5.2 -5.1 
CHEMBL1096093 -5.7 -5.4 -5.4 -5.2 -5.1 -5 -4.9 -4.9 -4.8 -4.7 
CHEMBL141909 -5.7 -5.7 -5.5 -5.5 -5.3 -5.3 -5.1 -5.1 -5 -5 
CHEMBL1767031 -5.7 -5.1 -5 -5 -4.9 -4.8 -4.7 -4.6 -4.6 -4.5 
CHEMBL1767033 -5.7 -5.7 -5.4 -5.3 -5.2 -5 -5 -4.9 -4.9 -4.9 
CHEMBL2046609 -5.7 -5.4 -5.3 -5.3 -5.3 -5.2 -5.2 -5.2 -5.1 -5.1 
CHEMBL2046614 -5.7 -5.6 -5.5 -5.5 -5.4 -5.3 -5.2 -5.2 -5.2 -5.1 
CHEMBL2046618 -5.7 -5.4 -5.2 -5.1 -5.1 -5 -5 -4.9 -4.9 -4.8 
CHEMBL2179618 -5.7 -5.6 -5.5 -5.4 -5.3 -5.3 -5.2 -5.2 -5.1 -5 
CHEMBL2333342 -5.7 -5.5 -5.4 -5.3 -5.2 -5.2 -5.2 -5.2 -5.2 -4.9 
CHEMBL245548 -5.7 -5.6 -5.5 -5.5 -5.5 -5.5 -5.4 -5.4 -5.4 -5.4 
CHEMBL261272 -5.7 -5.5 -5.5 -5.3 -5.1 -5.1 -5.1 -5 -4.9 -4.7 
CHEMBL271949 -5.7 -5.5 -5.4 -5.3 -5.2 -5.2 -5.1 -5.1 -5 -5 
CHEMBL356769 -5.7 -5.6 -5.5 -5.4 -5.3 -5.3 -5.2 -5.1 -5 -5 
CHEMBL403323 -5.7 -5.6 -5.5 -5.3 -5.3 -5.3 -5.2 -5.1 -5.1 -5 
CHEMBL453953 -5.7 -5.6 -5.5 -5.4 -5.3 -5.3 -5.3 -5.3 -5.2 -5.2 
CHEMBL455395 -5.7 -5.1 -4.9 -4.7 -4.7 -4.7 -4.6 -4.6 -4.5 -4.5 
CHEMBL462210 -5.7 -5.6 -5.5 -5.4 -5.4 -5.3 -5.3 -5.2 -5.2 -5.2 
CHEMBL471174 -5.7 -5.7 -5.6 -5.5 -5.5 -5.2 -5.2 -5.2 -5.2 -5.1 
CHEMBL473836 -5.7 -5.3 -5.2 -5.2 -5.2 -5.1 -5.1 -5.1 -5.1 -5 
CHEMBL481719 -5.7 -5.4 -5.2 -5.2 -5 -4.9 -4.9 -4.8 -4.7 -4.7 
CHEMBL494526 -5.7 -5.5 -5.5 -5.4 -5.3 -5.3 -5.3 -5.3 -5.2 -5.1 
CHEMBL497331 -5.7 -5.5 -5.4 -5.3 -5.3 -5.3 -5.3 -5.2 -5.2 -5.1 
CHEMBL507114 -5.7 -5.7 -5.7 -5.6 -5.3 -5.3 -5.3 -5.3 -5.3 -5.3 
CHEMBL507592 -5.7 -5.5 -5.2 -5.1 -5.1 -5.1 -4.9 -4.8 -4.7 -4.7 
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CHEMBL516600 -5.7 -5.7 -5.6 -5.6 -5.5 -5.5 -5.5 -5.4 -5.4 -5.4 
CHEMBL519943 -5.7 -5.7 -5.5 -5.4 -5.4 -5.4 -5.3 -5.2 -5.2 -5.1 
CHEMBL561483 -5.7 -5.5 -5.5 -5.2 -5.1 -5 -5 -5 -4.9 -4.9 
CHEMBL561604 -5.7 -5.4 -5.4 -5.2 -5.2 -5 -4.9 -4.8 -4.8 -4.7 
CHEMBL566807 -5.7 -5.6 -5.6 -5.6 -5.5 -5.5 -5.2 -5.1 -5.1 -5.1 
CHEMBL571505 -5.7 -5.7 -5.7 -5.6 -5.5 -5.3 -5.3 -5.1 -5 -5 
CHEMBL589311 -5.7 -5.2 -4.9 -4.7 -4.6 -4.6 -4.5 -4.5 -4.5 -4.5 
CHEMBL1094708 -5.6 -5.3 -5.3 -5 -5 -5 -4.9 -4.9 -4.9 -4.8 
CHEMBL1095136 -5.6 -5.5 -5.5 -5.4 -5.3 -5.3 -5.2 -5.2 -5.1 -5.1 
CHEMBL1095710 -5.6 -5.5 -5.4 -5.4 -5.4 -5.4 -5.3 -5.3 -5.3 -5.2 
CHEMBL1096986 -5.6 -5.6 -5.4 -5.3 -5.2 -5 -4.9 -4.9 -4.9 -4.8 
CHEMBL1630113 -5.6 -5.6 -5.4 -5.3 -5.3 -5.1 -5.1 -5.1 -5 -5 
CHEMBL1631912 -5.6 -5.5 -5.5 -5.4 -5.3 -5.3 -5.3 -5.2 -5.2 -5.2 
CHEMBL1631914 -5.6 -5.3 -4.9 -4.8 -4.8 -4.6 -4.5 -4.5 -4.5 -4.4 
CHEMBL1798003 -5.6 -5.4 -5.4 -5.3 -5.2 -5.2 -5.1 -5 -5 -5 
CHEMBL1800376 -5.6 -5.6 -5.3 -5.2 -5.1 -5.1 -5 -4.9 -4.8 -4.8 
CHEMBL1801238 -5.6 -5.5 -5.5 -5.5 -5.4 -5.4 -5.4 -5.3 -5.1 -5 
CHEMBL2018304 -5.6 -5.4 -5.2 -5 -4.4 -4.3 -4.3 -4.3 -4.1 -3.8 
CHEMBL2018448 -5.6 -5.5 -5.4 -5.4 -5.2 -5.1 -5 -5 -4.9 -4.8 
CHEMBL2047538 -5.6 -5 -5 -4.8 -4.6 -4.5 -4.4 -4.4 -4.3 -4.3 
CHEMBL2047692 -5.6 -5.3 -5.3 -5.1 -5.1 -5.1 -5.1 -5.1 -5.1 -5 
CHEMBL2047702 -5.6 -5.6 -5.5 -5.4 -5.4 -5.3 -5.3 -5.2 -5.2 -5.2 
CHEMBL216641 -5.6 -5.5 -5.5 -5.5 -5.5 -5.5 -5.4 -5.4 -5.4 -5.3 
CHEMBL2337867 -5.6 -5 -5 -4.9 -4.9 -4.7 -4.7 -4.6 -4.5 -4.3 
CHEMBL244199 -5.6 -5.6 -5.5 -5.5 -5.4 -5.4 -5.4 -5.3 -5.3 -5.2 
CHEMBL247653 -5.6 -5.4 -5.4 -5.3 -5.3 -5.2 -5.1 -4.9 -4.9 -4.9 
CHEMBL264411 -5.6 -5.2 -4.8 -4.7 -4.7 -4.6 -4.6 -4.6 -4.6 -4.6 
CHEMBL343717 -5.6 -5.4 -5.4 -5.4 -5.3 -5.3 -5.2 -5.2 -5.2 -5.2 
CHEMBL439842 -5.6 -5.5 -5.4 -5.3 -5.2 -5.2 -5.1 -5.1 -5 -5 
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CHEMBL466032 -5.6 -5.6 -5.6 -5.5 -5.4 -5.4 -5.3 -5.3 -5.2 -5.2 
CHEMBL468935 -5.6 -5.5 -5.4 -5.2 -5.2 -5.2 -5 -4.9 -4.8 -4.7 
CHEMBL473826 -5.6 -5.5 -5.5 -5.4 -5.4 -5.4 -5.4 -5.4 -5.3 -5.3 
CHEMBL474051 -5.6 -5.5 -5.4 -5.3 -5.3 -5.3 -5.2 -5.2 -5.1 -5 
CHEMBL474208 -5.6 -5.4 -5.4 -5.3 -5.2 -5.1 -5.1 -5.1 -5.1 -5 
CHEMBL475051 -5.6 -5.5 -5.4 -5.2 -5.2 -5.1 -5.1 -5.1 -5.1 -5 
CHEMBL492317 -5.6 -5.6 -5.5 -5.5 -5.4 -5.3 -5.3 -5.2 -5.2 -5.1 
CHEMBL494813 -5.6 -5.5 -5.3 -5.3 -5.3 -5.2 -5.1 -5 -5 -5 
CHEMBL573900 -5.6 -5.6 -5.6 -5.4 -5.3 -5.3 -5.2 -5.2 -5.2 -5.2 
CHEMBL585554 -5.6 -5.4 -5.4 -5.3 -5.2 -5.1 -5.1 -5.1 -5.1 -5.1 
CHEMBL138293 -5.5 -5.3 -5.1 -5.1 -5 -5 -4.9 -4.8 -4.8 -4.7 
CHEMBL1800249 -5.5 -5.2 -5.2 -5.1 -5.1 -5.1 -4.9 -4.9 -4.8 -4.8 
CHEMBL1800383 -5.5 -5.3 -5.3 -5.3 -5.3 -5.2 -5.1 -5.1 -5.1 -5 
CHEMBL1836143 -5.5 -5.4 -5.3 -5.1 -5.1 -4.7 -4.7 -4.7 -4.7 -4.6 
CHEMBL2018305 -5.5 -5.4 -5.2 -5.1 -5 -4.8 -4.7 -4.7 -4.6 -4.6 
CHEMBL2018451 -5.5 -5.4 -4.9 -4.8 -4.8 -4.7 -4.6 -4.4 -4.4 -4.4 
CHEMBL2047679 -5.5 -5.4 -5.4 -5.3 -5.3 -5.3 -5.3 -5.2 -5.1 -5.1 
CHEMBL2047694 -5.5 -5.1 -5 -5 -4.9 -4.9 -4.9 -4.8 -4.8 -4.7 
CHEMBL2048751 -5.5 -4.9 -4.9 -4.9 -4.8 -4.7 -4.7 -4.6 -4.6 -4.6 
CHEMBL221655 -5.5 -5.3 -5.3 -5.3 -5.2 -5.2 -5.1 -5.1 -5.1 -5 
CHEMBL2333339 -5.5 -5.3 -5.2 -5.2 -5.1 -5 -4.7 -4.5 -4.5 -4.5 
CHEMBL2333341 -5.5 -5 -4.9 -4.9 -4.7 -4.7 -4.6 -4.4 -4.4 -4.4 
CHEMBL260080 -5.5 -5.4 -5.4 -5.4 -5.3 -5.3 -5.3 -5.2 -5.2 -5.1 
CHEMBL389688 -5.5 -5.2 -5.2 -5.1 -4.8 -4.7 -4.7 -4.6 -4.6 -4.5 
CHEMBL461141 -5.5 -5.3 -5.2 -5.2 -5.2 -5.1 -5.1 -5.1 -5.1 -5 
CHEMBL475301 -5.5 -5.4 -5.1 -5 -4.9 -4.9 -4.9 -4.8 -4.7 -4.7 
CHEMBL475714 -5.5 -5.5 -5.3 -5.3 -5.2 -5.2 -5.2 -5.1 -5.1 -5 
CHEMBL484073 -5.5 -5.5 -5.2 -5.1 -5.1 -4.9 -4.9 -4.9 -4.9 -4.8 
CHEMBL511212 -5.5 -5.3 -5.3 -5.1 -4.9 -4.8 -4.7 -4.6 -4.5 -4.5 
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CHEMBL521652 -5.5 -4.9 -4.9 -4.8 -4.8 -4.7 -4.7 -4.7 -4.7 -4.6 
CHEMBL583130 -5.5 -5.5 -5.3 -5.3 -5.3 -5.2 -5.2 -5.2 -5.2 -5.1 
CHEMBL1095075 -5.4 -5.4 -5.1 -5.1 -5 -5 -4.9 -4.9 -4.9 -4.8 
CHEMBL1095449 -5.4 -5.3 -5.3 -5.2 -5.1 -5 -5 -4.9 -4.9 -4.7 
CHEMBL1096022 -5.4 -5.4 -5.2 -5.2 -5.2 -5.1 -5 -5 -4.9 -4.9 
CHEMBL146250 -5.4 -5.3 -5.3 -5.2 -5.2 -5.2 -5.2 -5.2 -5.1 -5 
CHEMBL1800244 -5.4 -5.4 -5.4 -5.1 -5 -5 -5 -4.9 -4.9 -4.9 
CHEMBL2018446 -5.4 -5.3 -5.3 -5.3 -5.2 -5.2 -5.2 -5.2 -5.1 -5 
CHEMBL259517 -5.4 -5.3 -5.2 -5.2 -5.2 -5.2 -5.2 -5.1 -5.1 -5.1 
CHEMBL400721 -5.4 -5 -4.9 -4.9 -4.8 -4.7 -4.7 -4.6 -4.6 -4.6 
CHEMBL427776 -5.4 -5.1 -5.1 -4.8 -4.8 -4.8 -4.6 -4.5 -4.5 -4.4 
CHEMBL447397 -5.4 -5.3 -5.2 -5.2 -5.2 -5 -5 -5 -5 -5 
CHEMBL467998 -5.4 -5.3 -5.3 -5.1 -5.1 -5.1 -5 -5 -5 -4.9 
CHEMBL473270 -5.4 -5.2 -5.2 -5 -5 -4.9 -4.9 -4.9 -4.7 -4.7 
CHEMBL481718 -5.4 -5.2 -5.1 -5.1 -5 -5 -4.9 -4.9 -4.8 -4.7 
CHEMBL496512 -5.4 -5.2 -5.1 -5 -4.9 -4.9 -4.9 -4.8 -4.7 -4.6 
CHEMBL517384 -5.4 -5.4 -5.4 -5.2 -5.2 -5.2 -5.1 -5.1 -4.8 -4.7 
CHEMBL564876 -5.4 -5.3 -5.3 -5.1 -5.1 -5.1 -5.1 -4.9 -4.9 -4.9 
CHEMBL1097017 -5.3 -5.3 -5.3 -5.3 -5.3 -5.3 -5.2 -5.2 -5.2 -5.2 
CHEMBL1800251 -5.3 -5.3 -5.2 -5.2 -5 -5 -5 -4.9 -4.9 -4.8 
CHEMBL1914708 -5.3 -5.2 -5.2 -5.2 -5.2 -5.2 -5.1 -5.1 -5.1 -5.1 
CHEMBL2018445 -5.3 -5.1 -5 -5 -5 -4.9 -4.9 -4.9 -4.8 -4.7 
CHEMBL247218 -5.3 -5.3 -5.2 -5.1 -5.1 -5 -5 -5 -4.9 -4.9 
CHEMBL253309 -5.3 -5.1 -5.1 -5.1 -4.9 -4.8 -4.7 -4.7 -4.7 -4.7 
CHEMBL261587 -5.3 -5.1 -5 -4.9 -4.8 -4.8 -4.8 -4.8 -4.8 -4.7 
CHEMBL482287 -5.3 -5.2 -4.9 -4.9 -4.9 -4.9 -4.8 -4.8 -4.7 -4.7 
CHEMBL1096705 -5.2 -5.1 -5.1 -4.9 -4.8 -4.7 -4.6 -4.6 -4.6 -4.5 
CHEMBL14227 -5.2 -5 -5 -5 -4.8 -4.8 -4.8 -4.8 -4.8 -4.7 
CHEMBL1630115 -5.2 -5.1 -5 -5 -5 -5 -5 -4.9 -4.8 -4.6 
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CHEMBL1798002 -5.2 -5.2 -5.2 -5.1 -5.1 -5 -5 -5 -5 -4.9 
CHEMBL1818136 -5.2 -5.1 -5 -5 -4.9 -4.9 -4.8 -4.7 -4.7 -4.6 
CHEMBL2337872 -5.2 -5 -5 -5 -4.9 -4.8 -4.7 -4.7 -4.7 -4.6 
CHEMBL440018 -5.2 -5.1 -5 -5 -5 -5 -5 -4.9 -4.8 -4.8 
CHEMBL460088 -5.2 -5.1 -5.1 -5 -5 -5 -4.9 -4.9 -4.8 -4.7 
CHEMBL480884 -5.2 -5.2 -5.1 -5 -5 -5 -4.9 -4.9 -4.9 -4.9 
CHEMBL512517 -5.2 -5 -5 -4.9 -4.8 -4.8 -4.8 -4.5 -4.5 -4.4 
CHEMBL515764 -5.2 -5.2 -5.1 -5 -4.9 -4.9 -4.8 -4.8 -4.8 -4.6 
CHEMBL573899 -5.2 -5.2 -5.1 -5.1 -5.1 -5 -5 -4.9 -4.9 -4.8 
CHEMBL1099094 -5.1 -5.1 -5.1 -5.1 -5.1 -4.9 -4.9 -4.8 -4.8 -4.7 
CHEMBL140525 -5.1 -5.1 -5 -4.8 -4.8 -4.5 -4.5 -4.5 -4.5 -4.5 
CHEMBL2047542 -5.1 -5.1 -5.1 -5 -5 -4.9 -4.8 -4.8 -4.8 -4.7 
CHEMBL2047685 -5.1 -5.1 -5 -4.9 -4.9 -4.8 -4.8 -4.7 -4.6 -4.6 
CHEMBL2177587 -5.1 -4.8 -4.4 -4.3 -4.3 -4.2 -4.2 -4 -3.9 -3.9 
CHEMBL2178343 -5.1 -5 -4.9 -4.8 -4.8 -4.7 -4.7 -4.6 -4.6 -4.6 
CHEMBL236902 -5.1 -5.1 -5.1 -5.1 -5 -5 -5 -5 -5 -4.9 
CHEMBL238596 -5.1 -5.1 -4.9 -4.9 -4.9 -4.9 -4.8 -4.8 -4.8 -4.8 
CHEMBL246199 -5.1 -5 -5 -5 -4.9 -4.7 -4.7 -4.7 -4.6 -4.6 
CHEMBL468595 -5.1 -5 -5 -4.9 -4.8 -4.8 -4.7 -4.7 -4.7 -4.6 
CHEMBL475618 -5.1 -5.1 -5 -5 -4.9 -4.9 -4.9 -4.9 -4.9 -4.9 
CHEMBL494990 -5.1 -5.1 -5 -4.9 -4.9 -4.9 -4.8 -4.8 -4.7 -4.7 
CHEMBL497760 -5.1 -5 -5 -4.9 -4.9 -4.8 -4.8 -4.8 -4.7 -4.7 
CHEMBL518821 -5.1 -5.1 -4.5 -4.4 -4.4 -4.1 -4.1 -4.1 -4 -3.9 
CHEMBL569306 -5.1 -5.1 -4.9 -4.8 -4.8 -4.8 -4.8 -4.8 -4.7 -4.7 
CHEMBL1094793 -5 -4.9 -4.9 -4.9 -4.9 -4.8 -4.8 -4.8 -4.8 -4.7 
CHEMBL1095120 -5 -5 -4.9 -4.9 -4.8 -4.7 -4.7 -4.7 -4.7 -4.6 
CHEMBL1095972 -5 -4.9 -4.8 -4.7 -4.6 -4.6 -4.6 -4.5 -4.5 -4.5 
CHEMBL1099095 -5 -4.8 -4.7 -4.7 -4.7 -4.6 -4.5 -4.5 -4.5 -4.5 
CHEMBL1165082 -5 -5 -4.8 -4.5 -4.5 -4.5 -4.5 -4.5 -4.4 -4.4 
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CHEMBL1214761 -5 -4.8 -4.7 -4.6 -4.6 -4.6 -4.5 -4.4 -4.2 -4.2 
CHEMBL140000 -5 -4.8 -4.7 -4.6 -4.6 -4.6 -4.5 -4.5 -4.5 -4.5 
CHEMBL152162 -5 -5 -5 -4.9 -4.6 -4.6 -4.6 -4.6 -4.6 -4.5 
CHEMBL154574 -5 -4.8 -4.8 -4.7 -4.7 -4.7 -4.6 -4.6 -4.6 -4.6 
CHEMBL1631913 -5 -4.8 -4.7 -4.7 -4.6 -4.5 -4.3 -4.2 -4.2 -4.1 
CHEMBL1767041 -5 -4.6 -4.5 -4.5 -4.5 -4.4 -4.3 -4.1 -4.1 -4 
CHEMBL1808672 -5 -4.9 -4.8 -4.6 -4.6 -4.5 -4.5 -4.5 -4.5 -4.5 
CHEMBL2337870 -5 -5 -4.9 -4.8 -4.7 -4.7 -4.6 -4.6 -4.6 -4.5 
CHEMBL466215 -5 -5 -5 -4.9 -4.9 -4.9 -4.9 -4.9 -4.8 -4.8 
CHEMBL481726 -5 -5 -4.9 -4.9 -4.8 -4.8 -4.7 -4.7 -4.6 -4.6 
CHEMBL493783 -5 -4.9 -4.8 -4.8 -4.6 -4.6 -4.6 -4.5 -4.5 -4.4 
CHEMBL503 -5 -5 -4.9 -4.8 -4.8 -4.7 -4.6 -4.6 -4.5 -4.5 
CHEMBL510856 -5 -4.8 -4.7 -4.7 -4.6 -4.6 -4.6 -4.5 -4.5 -4.5 
CHEMBL1095718 -4.9 -4.9 -4.6 -4.5 -4.5 -4.5 -4.3 -4.3 -4.3 -4.3 
CHEMBL180064 -4.9 -4.9 -4.8 -4.6 -4.5 -4.5 -4.4 -4.4 -4.4 -4.4 
CHEMBL2046610 -4.9 -4.8 -4.8 -4.8 -4.7 -4.7 -4.6 -4.6 -4.6 -4.5 
CHEMBL2047684 -4.9 -4.9 -4.7 -4.7 -4.6 -4.6 -4.6 -4.6 -4.5 -4.5 
CHEMBL2047698 -4.9 -4.7 -4.7 -4.6 -4.6 -4.5 -4.5 -4.5 -4.4 -4.3 
CHEMBL209453 -4.9 -4.9 -4.7 -4.7 -4.7 -4.6 -4.6 -4.6 -4.5 -4.5 
CHEMBL271741 -4.9 -4.8 -4.7 -4.7 -4.6 -4.6 -4.6 -4.6 -4.4 -4.4 
CHEMBL468527 -4.9 -4.9 -4.8 -4.7 -4.7 -4.6 -4.6 -4.6 -4.6 -4.4 
CHEMBL494527 -4.9 -4.9 -4.8 -4.8 -4.7 -4.7 -4.6 -4.6 -4.5 -4.5 
CHEMBL137875 -4.8 -4.7 -4.6 -4.6 -4.5 -4.5 -4.4 -4.4 -4.4 -4.4 
CHEMBL1630118 -4.8 -4.7 -4.6 -4.4 -4.4 -4.4 -4.3 -4.3 -4.3 -4.2 
CHEMBL1800245 -4.8 -4.7 -4.6 -4.6 -4.6 -4.5 -4.5 -4.5 -4.5 -4.5 
CHEMBL461142 -4.8 -4.6 -4.6 -4.6 -4.5 -4.5 -4.4 -4.4 -4.3 -4.3 
CHEMBL466459 -4.8 -4.8 -4.7 -4.7 -4.6 -4.6 -4.5 -4.5 -4.5 -4.5 
CHEMBL479602 -4.8 -4.7 -4.7 -4.7 -4.6 -4.5 -4.5 -4.4 -4.3 -4.3 
CHEMBL1630108 -4.7 -4.5 -4.5 -4.4 -4.3 -4 -4 -3.9 -3.9 -3.8 
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CHEMBL1800377 -4.7 -4.6 -4.5 -4.4 -4.3 -4.2 -4.2 -4.2 -4.1 -4 
CHEMBL454672 -4.7 -4.6 -4.6 -4.6 -4.5 -4.5 -4.4 -4.4 -4.4 -4.3 
CHEMBL494139 -4.7 -4.7 -4.7 -4.6 -4.6 -4.6 -4.6 -4.6 -4.6 -4.5 
CHEMBL505259 -4.7 -4.5 -4.4 -4.3 -4.3 -4.3 -4.2 -4.2 -4.2 -4.2 
CHEMBL1095451 -4.6 -4.5 -4.5 -4.4 -4.4 -4.4 -4.4 -4.3 -4.3 -4.3 
CHEMBL427135 -4.6 -4.6 -4.6 -4.4 -4.3 -4.2 -4.1 -4.1 -4.1 -4 
CHEMBL462370 -4.6 -4.4 -4.4 -4.4 -4.3 -4.3 -4.3 -4.3 -4.2 -4.2 
CHEMBL479601 -4.6 -4.5 -4.4 -4.4 -4.4 -4.3 -4.3 -4.3 -4.3 -4.3 
CHEMBL1767039 -4.5 -4.5 -4.4 -4.4 -4.3 -4.3 -4.2 -4.2 -4.2 -4.2 
CHEMBL393360 -4.5 -4.5 -4.4 -4.4 -4.4 -4.4 -4.3 -4.3 -4.2 -4.2 
CHEMBL405072 -4.5 -4.5 -4.4 -4.3 -4.3 -4.3 -4.2 -4.2 -4 -4 
CHEMBL409860 -4.5 -4.4 -4.4 -4.4 -4.3 -4.3 -4.2 -4.2 -4.1 -4.1 
CHEMBL487106 -4.5 -4.5 -4.4 -4.3 -4.1 -4.1 -4.1 -4.1 -4 -4 
CHEMBL523033 -4.5 -4.4 -4.2 -4.1 -3.7 -3.6 -3.5 -3.4 -3.1 -3.1 
CHEMBL1165292 -4.2 -3.7 -3.5 -3.5 -3.5 -3.4 -3.4 -3.2 -3.2 -3 
CHEMBL492311 -4.2 -4.1 -3.7 -3.7 -3.7 -3.7 -3.6 -3.5 -3.2 -3.1 
CHEMBL569122 -3.6 -3.6 -3.4 -3.3 -3.3 -3.3 -3.3 -3.3 -3.1 -3.1 
CHEMBL506834 -3 -3 -3 -2.9 -2.9 -2.8 -2.7 -2.6 -2.6 -2.6 
CHEMBL1095711 -1.2 -1.2 -1.1 -1 -1 -1 -0.9 -0.9 -0.9 -0.9 
CHEMBL186311 -1.2 -1.2 -1.2 -1.1 -1 -1 -0.9 -0.9 -0.9 -0.8 
CHEMBL2347008 -1.2 -1.2 -1.2 -1.2 -1.1 -1 -1 -1 -0.9 -0.9 
CHEMBL259826 -1.2 -1.2 -1.1 -1.1 -1 -1 -1 -0.9 -0.9 -0.9 
CHEMBL471043 -1.2 -1.2 -1.2 -1.1 -1 -1 -1 -1 -0.9 -0.9 
CHEMBL574365 -1.2 -1.2 -1.2 -1.1 -1 -1 -1 -0.9 -0.9 -0.9 
4.4. Pharmacophore Modelling 
10 Models were generated with the pharmacophore scores ranging from 0.7363 to 0.7905. 
The pharmacophore fit scores of the training set and test set compounds were calculated. The 
best pharmacophore is the one which has highest pharmacophore score. The HDAC6_1 with 
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score of 0.7905 was identified as best model. The pharmacophore fit score of the training set 
molecules were in the range of 55.4400 to 64.9900. The table below shows the ten models 
along with pharmacophore scores and figures. 
 























Figure 8. Pharmacophore models generated through Ligand-based Pharmacophore approach. 
The best model is represented at the top with the highest pharmacophre score. 
4.4.1. Database Screening 
The pharmacophore model HDAC6_1 was used to screen the drugbank database. The 
screening has led to identification of 106 hits which bear similar pharmacophoric features to 
the designed pharmacophore. The pharmacophore fit score of the compounds were in the 




Table 2: Hits identified by Pharmacophore model HDAC6_1 along with their 
pharmacophore fit score. 
Compound Name DrugBank_ID Pharmacophore fit Score 
273 DB00273 63.9355 
unnamed molecule DB00275 63.0052 
710 DB00710 54.9228 
xxxxxx DB00795 55.2828 
unnamed molecule DB01014 54.9996 
xxxxxx DB01250 54.4694 
unnamed molecule DB01834 54.6478 
unnamed molecule DB01877 55.7397 
IPO DB01980 56.2886 
unnamed molecule DB01973 54.0872 
GNR DB02036 56.3878 
CBP DB02049 63.3385 
GM6 DB02255 64.8937 
unnamed molecule DB02169 63.5983 
MM3 DB02350 55.9091 
unnamed molecule DB02367 64.139 
unnamed molecule DB02546 65.177 
unnamed molecule DB02560 56.3023 
ISA DB02570 55.5354 
unnamed molecule DB02625 56.1518 
LHY DB02652 55.6382 
unnamed molecule DB02677 54.1287 
FTT DB02767 54.8347 
unnamed molecule DB02691 63.3972 
DBD DB02827 63.1456 
65 
 
unnamed molecule DB02894 63.9548 
NHB DB02917 64.9878 
unnamed molecule DB02943 53.9076 
unnamed molecule DB03390 54.7957 
LVA DB03785 63.2229 
BAT DB03880 54.5914 
unnamed molecule DB04150 54.123 
BBH DB04140 63.7412 
SPI DB04232 64.5632 
INF DB04316 55.5788 
TSN DB04297 64.8024 
BB2 DB04310 64.6912 
BB1 DB04368 56.275 
4TR DB04600 63.7067 
4TZ DB04601 64.0293 
CA2 DB04656 64.0197 
114 DB06693 62.855 
28 DB06830 55.2849 
99 DB06837 64.5643 
1C2 DB06887 63.972 
294 DB06945 56.0343 
252 DB06931 55.0314 
2NI DB06971 57.0963 
2UN DB06989 64.2485 
37A DB07026 63.7 
347 DB07013 63.5403 
4NH DB07121 63.6123 
4HD DB07111 55.1889 
541 DB07145 63.5793 
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4UN DB07127 64.0977 
7MR DB07246 55.8185 
915 DB07290 64.8206 
AGE DB07350 64.0483 
B28 DB07409 54.3209 
B08 DB07404 54.3492 
B29 DB07410 54.4791 
C0E DB07510 63.303 
C1E DB07516 63.6985 
B76 DB07426 55.067 
C6L DB07532 55.1593 
C90 DB07536 55.6095 
CTF DB07596 55.7044 
D28 DB07616 62.9551 
ENT DB07719 54.9189 
GB4 DB07818 56.5254 
GB5 DB07819 56.187 
FBD DB07754 54.3048 
GVR DB07861 56.5265 
H23 DB07873 54.1856 
HPX DB07914 63.5385 
HOC DB07907 55.6448 
HXD DB07930 54.9674 
HTA DB07926 64.2885 
IH6 DB07964 56.5736 
J54 DB08007 55.0421 
JT5 DB08029 55.4295 
JT6 DB08030 56.8622 
KEL DB08040 64.4558 
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KI2 DB08041 55.099 
M5P DB08161 54.6816 
MP2 DB08199 54.5152 
NGH DB08271 55.7503 
NVC DB08310 64.1814 
PLH DB08403 64.2109 
PO1 DB08416 55.7042 
RO4 DB08482 64.7132 
RP4 DB08485 63.9443 
RS1 DB08490 63.5953 
RRS DB08489 63.8256 
RS2 DB08491 56.8171 
S17 DB08505 64.737 
SB7 DB08523 56.4279 
SB9 DB08525 56.45 
SB8 DB08524 64.8359 
SK2 DB08549 63.1838 
SRB DB08565 55.2985 
SRD DB08566 54.828 
V36 DB08693 56.4208 
V35 DB08692 56.1467 
WR2 DB08733 64.2887 



























Figure 9. Images I – VI show the hits identified from the Drugbank by Pharmacophore 
Model. 
4.5. Quantitative Structure Activity Relationship 
4.5.1. Model Generation 
McQSAR generated 5 models after 100 generations with input as 128 training set molecules. 
The models is represented by a equation which signifies the relation between the activity and 




values of the model were found to be 
0.706566 and 0.726806 respectively. The equation representing the model is given below 



















In the above equation max, min, plus and mul are binary operators representing maximum, 
minimum, addition and multiplication respectively, whereas exp, neg, log, sqrt, gauss, spline 
and qspline are unary operators representing exponential, negation, logarithm, squareroot, 
gaussian function, knot and knot to power of 2 respectively. 
The descriptors that are used in the above equation are  
SHBint3 - Sum of E-State descriptors of strength for potential Hydrogen Bonds of path length 3 
MDEC-12 - Molecular distance edge between all primary and secondary carbons. 
 
4.5.2. Prediction of Activity 
IC50 values for 106 compounds identified as hits from DrugBank by pharmacophore model 
was predicted. The IC50 values were in the range of 0.923136 nM to 8473.64 Nm. The table 
below presents the Drugbank hits along with their predicted IC50 and molecular weights. 
Table 3: IC50 values predicted by QSAR model generated by McQSAR 




1 DB01980 306.1 0.923135814 
2 DB08040 294.303 0.92436842 
3 DB07516 252.65 0.925463937 
4 DB07914 218.205 0.930439202 
5 DB08482 401.498 0.932110714 
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6 DB02827 466.442 0.934988997 
7 DB04656 310.342 0.935356352 
8 DB08485 358.408 0.935603634 
9 DB08199 312.342 0.936417454 
10 DB08041 329.347 0.938307959 
11 DB07536 437.488 0.939817007 
12 DB07754 402.395 0.941229651 
13 DB04150 576.122 0.945530408 
14 DB08007 238.24 0.951642874 
15 DB02652 224.213 0.962345678 
16 DB04316 224.213 0.962345678 
17 DB02677 361.177 0.965097076 
18 DB02560 345.564 0.965837359 
19 DB01834 501.552 0.967256373 
20 DB07510 254.186 0.968741489 
21 DB07410 448.3 0.980597022 
22 DB07404 434.316 0.980755856 
23 DB07409 434.316 0.981379722 
24 DB07873 346.294 0.985108848 
25 DB00710 319.229 0.986485509 
26 DB06931 304.214 0.986880687 
27 DB03390 191.182 0.988267105 
28 DB06830 276.161 0.98847368 
29 DB07426 450.315 0.989274171 
30 DB07246 404.361 0.991569934 
31 DB01973 259.279 1.293930649 
32 DB07907 160.211 1.368626674 
33 DB02943 383.463 1.504042125 
34 DB08491 391.438 1.88357102 
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35 DB02049 425.883 2.555912606 
36 DB08693 258.486 4.373982086 
37 DB08692 258.486 4.373982086 
38 DB06945 445.41 5.03133228 
39 DB02570 308.136 5.883137516 
40 DB02169 805.003 6.33041235 
41 DB04297 302.368 7.959027403 
42 DB07964 398.497 9.704027084 
43 DB02350 374.476 11.00246511 
44 DB02546 264.32 11.91434029 
45 DB06837 370.399 14.91969689 
46 DB08489 456.578 20.62718673 
47 DB07026 383.398 20.73862697 
48 DB08523 181.232 21.59384601 
49 DB02036 238.263 25.9352238 
50 DB07121 413.512 26.30449691 
51 DB04310 385.498 26.65937723 
52 DB08565 274.1 28.59433494 
53 DB08566 274.1 28.59433494 
54 DB03880 477.64 29.0255194 
55 DB02367 435.516 34.92207173 
56 DB07145 433.5 36.11602958 
57 DB08733 455.572 37.65390304 
58 DB08271 316.373 38.42111817 
59 DB08490 425.883 42.47662477 
60 DB07532 217.262 51.40081439 
61 DB02917 389.449 55.60578805 
62 DB02691 465.623 58.53558998 
63 DB04368 329.435 65.72945026 
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64 DB06971 311.335 66.98537608 
65 DB01877 345.371 67.23106641 
66 DB08029 350.39 67.89378175 
67 DB07350 284.31 85.78275699 
68 DB08030 282.294 86.73612184 
69 DB07818 232.063 98.14315159 
70 DB07819 197.618 109.7539097 
71 DB04232 449.478 114.5829502 
72 DB04140 419.452 114.6700495 
73 DB07861 420.481 140.6662792 
74 DB08310 359.42 340.3063085 
75 DB02255 388.461 347.0084097 
76 DB00795 398.393 624.3383323 
77 DB01014 357.318 624.3383323 
78 DB01250 302.239 624.3383323 
79 DB02894 361.346 624.3383323 
80 DB04600 449.282 624.3383323 
81 DB04601 370.386 624.3383323 
82 DB07616 344.36 624.3383323 
83 DB08161 224.319 624.3383323 
84 DB08860 421.461 624.3383323 
85 DB00273 339.362 652.5743508 
86 DB08549 419.452 685.0306447 
87 DB07290 346.374 776.4616313 
88 DB07013 465.563 1020.234487 
89 DB02767 244.37 1307.073471 
90 DB03785 422.555 1307.073471 
91 DB06693 408.528 1307.073471 
92 DB06989 407.438 1307.073471 
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93 DB07111 344.488 1307.073471 
94 DB07127 455.487 1307.073471 
95 DB07596 404.523 1307.073471 
96 DB07930 216.317 1307.073471 
97 DB08416 460.565 1307.073471 
98 DB08403 349.425 1315.164265 
99 DB06887 385.435 1432.385777 
100 DB07719 385.435 1432.385777 
101 DB00275 446.502 1475.230898 
102 DB07926 379.451 2307.0659 
103 DB08524 285.295 3773.722837 
104 DB08505 429.306 5855.715927 
105 DB08525 194.23 8299.272031 
106 DB02625 189.209 8473.639821 
4.6. Estimation of Free Binding Energy 
The binding energy for 58 compounds were estimated by Autodock vina. 8 molecules 
possessing binding energy less than -7 were selected for interaction studies. The top three 
binding poses were analysed for the presence of hydrogen bonds. It was found that most of 
the hydrogen bonding is with the residue ALA 617, present in the binding pocket. The table 
below summarizes the results of docking. 
Table 4. Binding energies of top Drugbank hits along with their hydrogen bonding residues. 
DrugBank_ID Binding Energies of top three conformation 
DB01250 





















-7 -6.8 -6.8 
 
TYR 570, ALA617 
 
DB07026 




-7.3 -7.3 -7.1 
 
LEU548,  ALA617 TYR 570,ALA617 
DB08549 
-7.2 -6.6 -6.6 








Figure 10. Docked conformations showing interactions between protein and ligand with 

























The need for specific inhibitors of Histone deacetylase 6 without affecting the 
function of other crucial HDACs is addressed in the present study. A rigorous 
screening procedure involving search for compounds in drugbank by the built 
pharmacophore, prediction of activity by QSAR and docking studies has led to the 
identification of 8 compounds that could prove to be a potential inhibitors of HDAC6. 
The work also emphasized on the importance of the structure of protein in the process 
of drug discovery. The need for structure was addressed by building a modelled 
protein using multiple templates. Most of the compounds discovered so far are 
hydroxamic acid based small molecules. The present study is able to look beyond 
them at compounds such as Benzenoids, Glycosides, Steriod derivatives, Ethers, 
Pyrrolidines and Carboxylic acids.  A highly efficient pharmacophore developed in 
this study could be further used to screen compounds from various other databases 
such as NCI, ZINC, etc. A further docking study against its closest isoforms may help 
in establishing its specificity against HDAC6. The suggested compounds could be 
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